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In the last decade the treatment of metastatic melanoma (MM) has been revolutionized and 
changed the life of many patients, offering prolonged survival and improved symptom 
control. These treatment strategies have also changed the way we treat malignancies in 
general and the treatment of melanoma has been the role model for new treatment strategies.  
Even though there has been a revolution that we have been part of, this revolution comes with 
responsibilities as many patients do not benefit from the new treatments and many patients 
experience toxicity. One key responsibility is to broaden our knowledge about tumor 
immunology and immunotherapy and to identify predictive biomarkers that allow for 
preselection of patients in order to identify patients who benefit from specific therapies and 
spare other patients from treatments, with side effects, that they will not benefit from. In 
addition, we have a societal and an ethical responsibility, as the treatments are costly and 
some of the side effects result in prolonged hospitalizations and lowered quality of life for the 
patients affected. We also have a responsibility not to be totally blinded by the success of the 
newly approved therapies, but to be open-minded and keep other well documented therapies 
in mind when recommending treatment strategies. 
As many new treatments target the immune system, the chance to identify predictive 
biomarkers most likely lies within studies of the immune system before, during and after 
treatment, to see if changes in different immune cell compartments can be related to response 
and toxicity.  
The overall aim of this thesis is to find biomarkers that correlate with response and toxicity to 
therapy with immune check-point inhibitors (ICI) and to study mechanisms in the immune 
system, in addition to those related to T-cells, during treatment with anti-CTLA 4 and anti-
PD1 antibodies. In addition, we conducted a phase I trial with adoptive T cell therapy (ACT) 
with or without dendritic cell (DC) vaccination, with the intention to explore an additional 
safe and effective treatment strategy to patients progressing on or not responding to immune 
checkpoint inhibitors (ICI). 
In paper I and II we performed comprehensive immune monitoring of patients treated with 
ICI; in paper I with anti-CTLA-4 antibodies and in paper II with anti-PD-1 antibodies. In 
paper I we observed that patients benefitting from treatment with anti-CTLA-4, and 
experiencing prolonged overall survival, had decreasing monocytic myeloid-derived 
suppressor cells (MDSCs) during treatment. It was also observed that CD8+ effector memory 
T cell frequencies at the end of treatment were higher in patients with clinical benefit and 
correlated with longer survival. In addition to this, it was observed that in patients 
experiencing toxicity from treatment there was a correlation between the amount of 
eosinophil granulocytes and the onset of toxicity.  In paper II it was observed that two distinct 
cell types could be correlated with overall survival, neutrophil granulocytes and MDSCs. In 
addition, it was observed that patients experiencing long progression free survival (PFS) had 
low frequency of CD69+ natural killer (NK) cells and low frequency of monocytic MDSCs at 
baseline.                                                                                                                                       
In paper III we could state that it was feasible and safe, with limited toxicity, to conduct a 
clinical trial with ACT with or without DC vaccination. In addition, we observed that four out 
of five patients treated with ACT and DC vaccination responded to the treatment.  
It is of great importance to find predictive biomarkers that could offer pre-selection of 
patients and the data shown in paper I-II suggest that some of the explored markers could be 
implemented in a clinical setting, but need to be further validated in prospective clinical 
studies. In paper III it was shown that ACT with DC vaccination, as a novel treatment is safe, 
brings benefit to patients and could be offered to a limited number of appropriately selected 
patients.   
 
 
LIST OF SCIENTIFIC PAPERS 
 
I. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 
effector memory T cells in longterm survivors with advanced melanoma                         
Yago Pico de Coana, Maria Wolodarski, Isabel Poshke, Yuya Yoshimoto, 
Yuan Yang, Maria Nyström, Ulrika Edbäck, Suzanne Egyhazy Brage, 
Andreas Lundqvist, Giuseppe Masucci, Johan Hansson, Rolf Kiessling 
Oncotarget, 2017, Vol 8, pp: 21539-21553 
 
II. PD-1 checkpoint blockade in advanced melanoma patients: NK cells, 
monocytic subsets and host PD-L1 expression as predictive biomarker 
candidates                                                                                                                  
Yago Pico de Coana, Maria Wolodarski, Irene van der Haar Ávila, Takahiro 
Nakajima, Stamatina Rentouli1, Andreas Lundqvist, Giuseppe Masucci, 
Johan Hansson, Rolf Kiessling                                                                    
OncoImmunology,2020, vol 9, NO.1, 1-14 
 
III. Complete and long-lasting clinical responses in immune checkpoint 
inhibitor-resistant, metastasized melanoma treated with adoptive T cell 
transfer combined with DC vaccination                                                                                                      
Tanja Lövgren*, Maria Wolodarski*, Stina Wickström*, U. Edbäck , E. 
Martell, K.Markland, P. Blomberg, M. Nyström, A. Lundqvist, H. Jacobsson , 
G. Ullenhag, P. Ljungman, J. Hansson, G. Masucci, R. Tell , I. Poschke, L. 
Adamson, J. Mattsson, R. Kiessling                                                                                
Oncoimmunology, Volume 9, 2020, NO1, 1-11 
  
CONTENTS 
1 Introduction ..................................................................................................................... 9 
1.1 Background ............................................................................................................ 9 
1.1.1 Terminology .............................................................................................. 9 
1.1.2 A brief early history of melanoma ............................................................ 9 
1.1.3 The puzzling behavior of the disease ..................................................... 10 
1.1.4 Epidemiology .......................................................................................... 10 
1.1.5 The primary lesion .................................................................................. 11 
1.1.6 Pathology ................................................................................................. 11 
1.1.7 Riskfactors ............................................................................................... 12 
1.1.8 Treatment of primary disease ................................................................. 12 
1.1.9 Classification, staging and follow-up ..................................................... 13 
1.1.10 Prevention; primary and secondary ........................................................ 13 
1.1.11 Prognosis ................................................................................................. 14 
1.2 The immune system and immune responses to tumor ....................................... 15 
1.2.1 Division of the immune response; innate and adaptive ......................... 15 
1.2.2 Immune cells and activities of importance in cancer immunity ............ 17 
1.2.3 Immune response to cancer..................................................................... 23 
1.2.4 Immunoediting ........................................................................................ 26 
1.2.5 Immunogenic cancer ............................................................................... 27 
1.3 Systemic treatments of advanced disease ........................................................... 28 
1.3.1 Historical/earlier systemic treatments of advanced disease ................... 28 
1.3.2 The new revolutionizing treatments of advanced disease...................... 31 
1.3.3 Resistance to check-point inhibition....................................................... 39 
1.3.4 Cold and hot tumors ................................................................................ 42 
1.3.5 New treatment combinations and treatment sequence ........................... 43 
1.3.6 Biomarkers .............................................................................................. 44 
1.3.7 Additional promising but not approved treatments ................................ 49 
1.4 Final reflections from a clinician ........................................................................ 50 
2 Aims of the thesis .......................................................................................................... 51 
2.1 Paper I .................................................................................................................. 51 
2.2 Paper II ................................................................................................................. 51 
2.3 Paper III ............................................................................................................... 51 
3 Patients and methods ..................................................................................................... 53 
3.1 Patients ................................................................................................................. 53 
3.1.1 Paper I ...................................................................................................... 53 
3.1.2 Paper II .................................................................................................... 53 
3.1.3 Paper III ................................................................................................... 53 
3.2 Methods ............................................................................................................... 54 
3.2.1 Paper I ...................................................................................................... 54 
3.2.2 Paper II .................................................................................................... 54 
3.2.3 Paper III ................................................................................................... 55 
 
 
4 Results ............................................................................................................................ 57 
4.1 Paper I .................................................................................................................. 57 
4.2 Paper II ................................................................................................................. 57 
4.3 Paper III ............................................................................................................... 58 
5 Conclusions, Discussion and Implications ................................................................... 60 
5.1 Paper I .................................................................................................................. 60 
5.2 Paper II ................................................................................................................. 60 
5.3 Paper III ............................................................................................................... 61 
6 Future perspectives ........................................................................................................ 62 
7 Acknowledgements ....................................................................................................... 65 
8 References ..................................................................................................................... 67 
 
  
LIST OF ABBREVIATIONS 
ACT Adoptive cell therapy 
ADCC Antibody-dependent cellular cytotoxicity 
AE Adverse event 
AJCC American Joint Committee on Cancer 
APC Antigen presenting cell 
Arg1 Arginase-1 
CDKN2A Cyclin-dependent kinase inhibitor 2A 
CR Complete response 
CTL Cytotoxic T cells 
CTLA-4 Cytotoxic T-lymphocyte antigen -4 
DC Dendritic cell 
FDA US Food and Drug Administration 
Gp100 Glycoprotein 100 or melanocyte protein 
ICOS Inducible T-cell costimulator 
IDO Indoleamine-pyrrole 2,3-dioxygenase 
IFN-γ Interferon gamma 
IL-2 Interleukin-2 
ICI Immune check-point inhibitors 
LDH Serum lactate dehydrogenase 
MHC Major histocompatibility complex 
MAGE-A3 Melanoma-associated antigen 3 
MAPK Mitogen-activated protein kinase pathway 
MART-1/MelanA Melanoma antigen recognized by T cells 
MDSC Myeloid Derived Supressor Cells 
MMR Mismatch repair 
MR Mixed response 
MSI Microsatellite instability 
NK cells Natural Killer cells 
NLR Neutrophil to Lymphocyte Ratio 
NY-ESO-1 Cancer/testis antigen 1 
 
 
iNOS inducible NO synthase 
ORR Overall response rate 
OS Overall survival 
PD-1 Programmed death-1 
PFS Progression free survival 
PR Partial response 
PTEN Phosphatase and tensin homolog 
RFS Relapse free survival 
RLC Relative lymphocyte count 
ROS Reactive Oxygen Species 
SCC Squamous cell carcinoma 
TAA Tumor-associated antigen 
TCR T cell receptor 
TGF-β   Transforming growth factor-beta 
TIL Tumor infiltrating lymphocyte 
TMB Tumor mutational burden 
TME Tumor micro environment 
TNF-α Tumor necrosis factor –alfa 
TNM Tumor Node Metastses 
TSA Tumor-specific antigen   
UV Ultra violet 
VEGF Vascular endothelial growth factor 







In the last decade the treatment of melanoma has changed enormously. When I was a junior 
oncologist around the year of 2006, working in the clinical ward, I remember the often rather 
young patients with metastatic melanoma having the stormy course of disease that only 
melanoma can have. From being almost free of symptoms from the disease they deteriorated 
very rapidly and succumbed in a very brief time, often leaving families with many questions 
and unsolved matters. 
The disease itself is rather mysterious, originating from a tiny spot where sunlight, which 
people here in the north seek so much, plays a major role with UV radiation being the most 
important external risk factor [1]. This light that many of us yearn causes cellular and 
biological effects which result in DNA damage and mutations, cellular growth stimulation 
and effects on the immune system and inflammation, that can cause cancer, which, if it is not 
dealt with in time, can be a potentially deadly disease. 
1.1.1 Terminology 
The word melanoma originates from the greek “melas” meaning dark and “oma” meaning 
process/tumor (see below).The word melanoma was earlier used in a broader sense to 
describe any melanocytic tumor, but today the narrower sense only referring to malignant 
types has become dominant. 
1.1.2 A brief early history of melanoma 
In approximately the 5th century BC, Hippocrates was the first to record a description of 
melanoma [2]. As early as in the middle of the 17th century a British surgeon, Highmore, 
among others referred to a condition of “fatal black tumors with metastases and black fluid in 
the body” [2]. After that, descriptions of melanoma are rare until the middle of the 18th 
century when the surgeon John Hunter was recorded to be the first to perform surgery for 
melanoma on a patient [2]. In the early 19th century a French physician, Rene Laennec was 
the first to describe melanoma as a disease. He had observed dark lesions in multiple organs 
of patients and he described the condition, with similarity to Hippocrates’s description, as 
melanosis, although it was the pathologist Carswell who re-introduced the term melanoma 
since Hippocrates [2]. After that an English general practitioner, William Norris, was the first 
to study melanoma more in detail and to make correlations between pathology, epidemiology 
and management of melanoma [3]. In the 19h century the knowledge about melanoma 
progressed and guidelines for surgical treatment of melanoma took form [2]. 
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1.1.3 The puzzling behavior of the disease 
Melanoma is also special in the way that it is both frequently affected by the immune system 
and in turn can affect the immune system in a negative way. Spontaneous regression, both of 
the primary lesion and, more rarely, even of metastatic disease can be seen and this is 
reported to be more frequent for melanoma than for other malignancies [4]. The cancer can 
hide from the immune system after primary surgery, lay dormant for many years, then 
suddenly reappear and imitate other types of ailments or diseases, deceiving the patient and 
clinicians. Not seldom do clinicians meet patients who had their primary lesion removed 
many years ago, making them forget they even had a malignancy. Then something happens. 
May it be one of those rather soft lumps under the skin that are so easily taken for lipomas or 
may it be a few of those reddish dots that could be taken for rash or eczema or may it be those 
black-blue dots marking the skin in their distinct way. Or just that feeling that something has 
changed, that you feel more tired, or that you have a kind of pain that is difficult to put a 
finger on. These patients have often wandered through many contacts with healthcare, due to 
their diffuse symptomatology, and often after a rather long period it becomes clear that it is 
their previous melanoma that has come back and spread.                    
A relative of mine experienced melanoma in this way in the beginning of this century and 
sometimes the question is asked: what if? What if he had gotten the disease back today? 
Would he have been cured then? Could he have lived now but with a chronic disease? If the 
new treatments had been used in the clinic earlier, would he have responded? No one can tell 
but it makes one think how much has improved in the treatment of advanced disease and in 
what short period of time it has happened. In my lifetime up to now, the regimens of handling 
this disease have changed enormously and only during my time as practicing oncologist have 
there been tremendous changes. 
1.1.4 Epidemiology  
My relative got his primary lesion in the late 1970s or early 1980s. Since then the incidence 
of melanoma has increased very much: in the past decade, based on the age standardized 
incidence, there has been an increase with around 5 % per year for both women and men in 
Sweden [5]. Sweden is one of the countries in Europe with the highest incidence of 
melanoma [6]. In the Nordic countries the incidence is the highest in Denmark, Norway and 
Sweden but remarkably lower in Finland and Iceland [7].                                                                                                     
The  increase in incidence may be related to changes in life-style regarding sun exposure, 
with many more people seeking sun exposure also during winter time with holidays abroad 
and through indoor tanning in beauty salons [8].Today, about 4000 people per year in 
Sweden are diagnosed with primary invasive melanoma and it is the sixth most common 
malignancy among men and the fifth among women [9].The relative of mine lived in 
Karlstad, Värmland just below the middle of Sweden and the incidence also varies with 
latitude and is almost the double in the south of Sweden compared to the north of Sweden 
[10]. He was in his late 30s/beginning of his 40s when diagnosed and today the median age of 
diagnosis is 69 years among men and 65 years among women [11]. The lesion he had was 
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localized over one of the breasts and there is a difference between the genders regarding most 
common localization; for men it is more common on the trunk and for women more common 
on lower extremities [11]. 
1.1.5 The primary lesion 
Like for many others a close kin, his wife, observed a lesion that she thought had changed 
and that she thought stood out, an “ugly duckling”. In three of four cases of melanoma it is 
the patient him-/herself or a relative that notes the lesion [12]. It has been shown that male 
individuals living alone tend to seek healthcare more rarely and tend to present with thicker 
and more advanced primary lesions [13]. It is also shown that if the primary lesion is 
discovered by a physician, regardless of specialty, it is thinner than if the patient him-/herself 
discovers it [14]. Before my relative’s lesion was removed some time passed due to the fact 
that physicians did not consider that it looked atypical. However, anamnestic information 
about change and symptoms are important, even though the lesion itself seems to be 
unspecific, and should be guiding in making decision on further investigation [15]. In 20-
30% of cases of melanoma, the patient has turned to healthcare at several occasions regarding 
the lesion before it becomes removed, due to the difficulty to clinically diagnose a melanoma 
because of their vast variation in clinical presentation [16]. After having it removed and 
analyzed it was clear that it was a malignant melanoma that my relative had had.   
1.1.6 Pathology 
Melanoma is caused by malignant transformation and proliferation of melanocytes in the 
basal layer of the epidermis. 
Figure 1. Melanoma is caused by malignant transformation and proliferation of melanocytes (the cells 
producing melanin, the pigment, which gives rise to the color of the skin) in the basal layer of the epidermis. 




Earlier it was thought that the development of a malignant lesion went stepwise from a 
benign naevus through a dysplastic naevus to finally a malignant melanoma. In later years 
another theory has emerged; that melanocyte stem cells transform to melanoma stem cells, 
giving rise to melanoma without a precursor lesion [17]. This is supported by the fact that 
almost 70 % of melanomas occur de novo, without a precursor lesion such as a naevus 
[18][19].  
Melanoma tumors contain a large number of mutations, especially melanomas that occur on 
skin that has been exposed to excessive UV-radiation [20]. These mutations cause activation 
of many signaling pathways in the cells [21]. Several types of gene mutations are common, 
for instance activating mutations in genes such as BRAF or NRAS or loss of or inactivation of 
tumor suppressor genes such as CDKN2A (cyclin-dependent kinase inhibitor 2A) or PTEN 
(Phosphatase and tensin homolog). The most common mutation is the BRAFV600 mutation 
which also occurs early during melanoma development. BRAF mutation is present in about 
40-50% of cutaneous melanomas and it drives tumor progression through constitutive 
activation of the mitogen-activated protein kinase (MAPK) pathway [22]. 
1.1.7 Riskfactors 
Why did my relative get a melanoma, did he have any particular risk factors?                                               
The individual risk for melanoma is affected both by genetic and external factors such as sun 
habits [1][23, 24]. No one else in his family had had melanoma, but in 5-10% of the cases of 
cutaneous melanoma there is heredity for the disease [25]. He was fair skinned and had fair 
somewhat reddish hair, some freckles and rather few moles and most likely he had been 
burned in the sun earlier in life. In the end of the 1950s Henry Lancaster made the initial 
connection between ultraviolet radiation from exposure to sunlight and increased incidence 
on melanoma. This idea was supported by the further work of Lancaster and Nelson, who 
demonstrated that the characteristics of the skin had an impact on melanoma development, 
including skin color, texture, hair color, eye color and reaction to the sun [26].                                                                     
Risk factors should be weighed together in a general risk evaluation for each individual, 
where rare genetic alterations can contribute to a much higher risk than more common factors 
such as hair color or being burnt in the sun [27]. 
1.1.8 Treatment of primary disease 
After verification that the lesion was melanoma, my relative was operated again with local 
wide excision, but as far as I know no lymph node exploration. I remember his scar, a 
horizontal one right over one of the pectoral areas, a very distinct sign that was very obvious 
the times he joined us cousins for swimming.  
Already in the 1890s, Herbert Snow expressed the benefits of removing the tumor and 
surrounding glands as a method of prophylaxis. He believed that the excision of the tumor 
alone was an ineffective treatment and whenever possible the draining lymph glands should 
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be removed [2, 28]. In the very beginning of 1900s, William Handley analyzed the lymphatic 
spread of secondary melanoma on a woman’s leg, which formed the basis of a case study of 
the disease. He suggested that the surrounding subcutaneous tissue and lymph nodes should 
be removed [2]. Even today these observations and theories influence the primary treatment 
and also the follow-up guidelines, even though the width of the wide excision has varied over 
time as well as the opinion on how much of lymphoid glands should be removed.                                      
Today all invasive melanomas are treated surgically with wide local excision, the width 
depending on the thickness of the primary tumor [29].                                                               
Sentinel node biopsy, which was introduced in the beginning of the 1990s, is today 
recommended for melanomas thicker than 1 mm (T2-T4 tumors, for classification see below) 
[30]. Sentinel node is by definition the first lymph node that drains the skin area where the 
primary tumor is localized and is thus the best place to selectively look for metastases [31]. 
Sentinel node status is, in addition to tumor thickness, a strong prognostic factor [32-34], but 
the biopsy has no therapeutic value in itself. Lymph node exploration is performed only if 
sentinel node shows periglandular/pericapsular growth, if the patient is immune suppressed, if 
there are microsatellites around the primary and if there are more than tree positive sentinel 
nodes. This is based on two large trials, DeCOG-SLT and MSLT-2, both showing that there 
is no benefit to perform lymph node exploration due to positive sentinel node only [34, 35]. 
1.1.9 Classification, staging and follow-up 
Melanomas are classified according to the TNM system [36] and staged according to AJCC 
(American Joint Committee on Cancer) [37].   
The follow-up guidelines in Sweden are based on the classification above. This follow-up 
system has changed during the years, only since I started working as an oncologist. Back 
then, almost ten years ago, the follow-up system was more intense with much more frequent 
clinical check-ups. But as no survival benefit has been demonstrated by this and due to the 
fact that around 70% of the recurrences of melanoma are discovered at other time-points than 
at follow-up appointments (of asymptomatic patients) [38, 39], this has changed and the 
clinical check-ups are much less frequent today. 
1.1.10 Prevention; primary and secondary 
After the surgical treatment I recall that my relative very seldom spent time in the sun, often 
sought the shade and that he often wore a T-shirt on the beach, which for me as a child was 
very mysterious. His behavior was correct. When having had one melanoma, the risk of 
developing a new one is increased compared to someone that has not had melanoma [40].                                                                              
I remember more senior colleagues telling me about the 1990s when they travelled around 
Sweden staying in caravans visiting beaches to inform people on the beach of the risks of the 
sun, primary prevention. They told me about that period with something warm in the voice, 
that it had been a special time in their work-life and in their lives. Studies show that Swedes 
tend to sunbathe with the intention of getting tanned and that our beauty ideal is more tanned 
than in other European populations [41]. We Swedes also tend to protect ourselves less in the 
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sun and we burn more often than other nationalities [42]. Sun exposure and sun-burn early in 
life seems to be a special risk factor [43]. Sun exposure in childhood also affects the risk of 
developing many moles, which in turn is considered an increased risk factor [44]. It makes 
one wonder, with the increasing incidence of melanoma, if the “summer tours” should be 
taken into action again. 
1.1.11 Prognosis  
1.1.11.1 Prognosis in early stages 
My relative was cured from his primary melanoma. Sadly his melanoma recurred. What was 
the risk of that and could it have been prevented had he only acted or behaved differently? 
                                                                                                                  
The survival after having a melanoma depends on several factors, both clinical and 
histopathological, such as, age, gender, thickness of the tumor according to Breslow and 
whether the tumor had an ulceration [45] [13, 46].                                                                             
The prognosis in early stages of cutaneous melanoma is very good and almost all patients are 
cured after primary surgery with wide local excision.                   
The melanoma specific 5-year survival for T1 (0-1 mm thickness according to Breslow) 
melanomas is about 95%, but with increasing thickness the survival worsens to between 50 to 
75% for T4 tumors (>4 mm thick according to Breslow). The 5 year survival for stage III 
melanoma with regional lymph node metastases ranges between around 40%-around 80% 
[47].                                                                                                                                                      
There is nothing that the patient self can do in order to prevent the recurrence of disease, a 
question that often arises when patients come for information about relapsed disease. There is 
no type of food known to be beneficial or no certain way of living that could prevent the 
disease from recurring. 
1.1.11.2 Prognosis in advanced stage 
Samuel Cooper was the first to formally acknowledge in the 1840’s that advanced melanoma 
was untreatable and that “the only chance for benefit depends on early removal of the 
disease” [2]. Even today this statement remains true to a great extent.                                                      
Stage IV melanomas as a group has until recently had very poor prognosis, with a one year 
survival around 25 %, a two year survival around 10 % and a median overall survival about 
six to ten months [45]. Regarding the subtypes of stage IV melanoma, according to AJCC, 
there are differences in survival. Patients with distal metastases to the skin, soft tissue or 
distal lymph nodes (M1a) have the best overall survival if the serum lactate dehydrogenase 
(LDH) level is normal. LDH is an enzyme that catalyzes the conversion of lactate to pyruvate 
and back and it is found in almost all living cells. It is expressed to a large extent in body 
tissues and is released if there is tissue damage. Many cancers can elevate the LDH level. 
Patients with metastatic disease spread to the lungs (M1b) have an intermediate prognosis. If 
the disease has spread to any other organs and/or if the patient has an elevated LDH (M1c) 
and patients with brain metastases (M1d) have the worst prognosis [36, 37]. LDH level is 
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also a predictor of survival and elevated LDH at diagnosis of stage IV disease means a 
shorter survival than if LDH is normal [48]. The 1–2-year survival is between 40–60% in 
patients with normal LDH, compared to between 18–32% in patients with elevated LDH 
levels [37]. The number of distant sites involved is also a strong predictor of survival [49], 
but not included in the staging system. 
1.2 THE IMMUNE SYSTEM AND IMMUNE RESPONSES TO TUMOR 
One can wonder what went on in my relative’s body during these years before the primary 
melanoma occurred and was removed in the beginning of the 1980s until the disease recurred 
again. For certain his immune system was involved, both before the primary lesion was 
observed and removed, during the time he was free of disease, as well as when the disease 
had spread.  
The immune system is the defense system which protects individuals from dangers. To do so 
it utilizes a diversity of cells, molecules, and organs. In its simplest form, the immune system 
functions in the way that it identifies and eliminates dangerous elements. It requires two 
necessary activities: recognition of a danger agent or antigen by certain receptors on the 
surface of immune cells and, once the danger element is detected, it carries out effector 
responses, involving a variety of cellular behaviors that protect the individual [50, 51]. 
Communication between cells in the immune system occurs both through cell to cell contact, 
as well as through chemical signals that are secreted from one cell and received by others [50, 
51]. 
1.2.1 Division of the immune response; innate and adaptive 
The immune system can in a simple way be classified into two responses; the innate immune 
response and the adaptive immune response. The immune response to invasion by pathogen 
or tumor depends on collaboration and coordination of activities in both the innate and the 
adaptive immune system [51]. 
1.2.1.1 The innate immune response 
The innate immune system appeared early in animal evolution, as an essential response to 
infection [52]. It is often called the “more primitive” immune system which provides more 
immediate and somewhat more generalized defense and can be divided into immediate and 
induced components. The immediate innate immune system consists of epithelial barriers, 
mucus, enzymes and peptides that can be secreted by specific cells involved in this line of 
defense. The induced innate immune system is composed of white blood cells: granulocytes, 
macrophages, dendritic cells and Natural Killer (NK) cells, with phagocytic, cytotoxic and 
secretory activity. The innate immunity detects and destroys most microorganisms that enter 
the body within hours or even minutes. Its receptors recognize features that are common for 
many invading organisms and therefore it is very effective in discriminating between self and 
non-self. Furthermore, the innate immune response is one of the main drivers needed to 
activate the adaptive immune system [50, 51]. 
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1.2.1.2 The adaptive immune response 
The adaptive (or acquired) immune response evolved in early vertebrates and is much more 
specialized with the capacity of stronger immune response as well as immunological memory 
[53]. The adaptive immune response is antigen-specific and requires the recognition of 
specific "non-self" antigens during a process called antigen presentation.  
The adaptive immune system is composed by B and T lymphocytes derived from 
hematopoetic cells in the bone marrow [54]. B cells are involved in humoral response and T 
cells in cell-mediated response. Both B and T cells use specialized receptor molecules that 
recognize antigens in a very specific way. B cells produce immunoglobulins that recognize 
antigens in extracellular spaces. Immunoglobulins can either be bound to the membrane of 
the cell or secreted. T cells recognize antigens only after they have been processed by an 
antigen presenting cell (APC) and presented by "self" receptor on the APC’s surface, the 
major histocompatibility complex (MHC) [50, 51].  
The adaptive immune response is dependent on the innate for its activation and weak 





1.2.2 Immune cells and activities of importance in cancer immunity  
The cells of the immune system are a collection of blood cells which can be grouped into the 
major categories lymphocytes (T cells, B cells, NK cells) and myeloid cells (antigen 
presenting cells, macrophages, dendritic cells and granulocytic cells) [50, 51].                             
These cells are derived from a common hematopoetic stem cell in the bone marrow. 
 
 
Cells involved in antitumor immunity are cells involved both in the innate and adaptive 
immune response and the most important ones are lymphocytes, especially B cells, T cells, 
NK cells and antigen presenting cells. Macrophages and dendritic cells could be said to serve 
as bridges between the two branches of defense. 
1.2.2.1 Antigen presenting cells (APC) 
Antigen-presenting cells are crucial for effective adaptive immune response, as the 
functioning of both cytotoxic and helper T cells are dependent on APCs. Antigen presentation 
is the link between innate and adaptive response. It is also involved in defense against tumors. 
One major task of the antigen presenting cells is to scan the body for foreign agents and 
internalize them, degrade them into small parts and then present them to the T cells. Almost 
all cells can present antigen in some way. Professional antigen-presenting cells: macrophages, 
B cells and dendritic cells present foreign antigens to helper T cells using MHC class II, 
Figure 2.Major cells of the immune system 
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while all other nucleated cells use MHC class I to present antigens originating inside the cell 
to cytotoxic T cells.   
As mentioned above, antigen-presenting cells can be categorized in two major groups; non-
professional and professional.                                                                                                            
Non-professional APCs include all nucleated cells in the body. They utilize MHC class I 
molecule on their surface to present peptides originated from inside the cell, in contrast to the 
professional APCs, which present exogenous peptides through MHC class II. CD8+, 
Cytotoxic T cells are able to interact with the endogenous peptide presented in the MHC class 
I [55].                                                                                                                                         
Professional APCs express MHC class II molecules along with co-stimulatory molecules and 
pattern recognition receptors and they specialize in presenting antigen to T cells (CD4+) [56]. 
Professional APCs are very efficient at internalizing antigens, either by phagocytosis or by 
receptor-mediated endocytosis and processing the antigen into peptide fragments and then 
displaying those peptides, bound to the class II MHC molecule, on their membrane [56]. 
Professional APCs include dendritic cells, macrophages and B cells. In antitumor immunity, 
dendritic cells are considered the most potent APCs as they express high levels of co-
stimulatory molecules (such as CD80 and CD86) and have a large surface area and express 
high levels of MHC [50, 51]. 
1.2.2.2 T cell activation 
The most important lymphocytes in antitumor immunity are T cells and they are named for 
thymus, where they mature in humans. Progenitor T cells are derived in the bone marrow and 
they migrate to the thymus where they develop.   
Thymoctes are generated in the thymus where they generate a unique T cell receptor, TCR, a 
complex containing the CD3 co-receptor that can be used as a T cell marker. In order to 
recognize and destroy only invading pathogens and their antigens, the thymocytes undergo 
both positive and negative selection during their development in the thymus. Positive 
selection is the first step, in which only thymocytes that interact with MHC I or II survive. 
This process ensures that the selected T cells will have an MHC affinity to be able to interact 
with MHC and peptide complexes to carry out immune responses which are important 
functions for the host [57]. Most thymocytes are eliminated by apoptosis during positive 
selection. Those that survive positive selection go on to the negative selection process where 
thymocytes that are capable of strongly binding with "self" MHC peptides undergo apoptosis. 
This protects the host from having T cells that are capable of reacting to “self” molecules and 
thereby contribute to autoimmune reactions. This process is an important component of 
central tolerance. About 98% of thymocytes die off during the processes of positive and 
negative selection in the thymus. The remaining 2% that survive the selection process leave 
the thymus as immunocompetent naïve T cells. Already in the thymus CD4+ and CD8+ T 
cells are selected, but undergo further differentiation in the periphery to specialized cells 
which have different functions (see below). 
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Naïve T cells, after development in the thymus, recirculate to lymph nodes and then back to 
the bloodstream every 12 to 24 hours. This high speed of circulation results in a better chance 
that a T cell will meet the appropriate antigen. Naïve T cells enter lymph nodes through 
specialized regions and thereafter travel through regions of dendritic cell networks in order to 
meet the appropriate antigen. If a naïve T cell does not meet and bind to any of the 
MHC/antigen complexes it meets, it leaves the lymph node back to the bloodstream. If the 
naïve T cell instead meets the appropriate antigen presenting cell that expresses the right 
MHC/antigen, an activation program will be started [51].   
In order to be able to perform their effector functions, T cells have to be activated. The 
activation is a complex process which was initially described in 1970 as a two-step process 
[58].  Antigen presenting cells (APC) process antigens from damaged tissue and they migrate 
to lymph nodes where they present these antigens to T lymphocytes. The T cell receptor 
(TCR) recognizes the antigen that is presented in the major histocompatibility complex 
(MHC-I or MHC-II) on the surface of the antigen presenting cells. This is called signal one. 
In the original activation model, the second signal needed to fulfill T cell activation implied 
the binding of CD28 to its B7 ligands, (CD80 and CD86). In the absence of this second 
costimulatory signal, no activation would take place. 
 
  
Figure 3. T cell activation is a multistep process. Signal one being the recognition of the TCR of the 
antigen presented in the MHC complex. The next signal, two is the co-stimulatory interaction where CD28 
binds to one of its ligands. Both signal one and two are needed in order for activation to take place. 
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It is now known that T cell activation is fine-tuned with great precision using a series of co-
stimulatory and co-inhibitory pathways that act together in order to deliver the precise 
amount of activation for T cells, enabling them to carry out their effector functions whilst 
preventing excessive immune responses. CD28 is the dominant co-stimulatory receptor on 
naïve T cells and other cells have other co-stimulatory receptors that are structurally related 
CD28, for instance ICOS (Inducible T cell co-stimulator) expressed by memory and effector 
T cells. Since activation cannot take place unless both signals are delivered, the receptors 
involved in the second signal act as molecular checkpoints for the activation of the immune 
response. These immune checkpoints are one of the main actors of peripheral tolerance, the 
mechanism which prevents the T cells that have escaped selection in the central tolerance 




Figure 4. Different co-stimulatory and co-inhibitory pathways.                                                                         




1.2.2.3 T cell differentiation  
Once activated T cells will be ready to carry out their effector functions, which rely on the T 
cell subtype. Some subtypes of relevance to this thesis are: 
T helper cells with the surface expression of CD4, provide help and assistance to other cells 
and are involved in the activation of cytotoxic T cells. They activate or inactivate other types 
of cells by secreting cytokines. Activated T helper cells can differentiate into at least five 
different subpopulations and each of these subtypes is characterized by a certain set of 
effector cytokines [50, 51]. The T helper cells of main importance for anti-tumor immunity 
are Th1 and Th2. Th1 secrete the cytokines interferon gamma (IFN-γ) and tumor necrosis 
factor –alfa (TNF-α). They are involved in producing an anti-inflammatory response and they 
could activate macrophages and are involved in the activation of cytotoxic T cells as part of 
the defense against intracellular bacteria, viruses and tumors. Th2 secrete the cytokines 
interleukin 4, 5 and 13 (IL-4, IL5, IL-13). They are mostly involved in aiding the 
differentiation and antibody production by B cells [59].  
Cytotoxic T cells (CTL) with the surface expression of CD8 have, after being activated, the 
ability to recognize and kill cells that are infected or transformed. These cells present foreign 
(or transformed) antigens on their surface via MHC class I. CTL kill by establishing an 
immunological synapse with the foreign target and deliver signals that cause apoptosis, “the 
kiss of death”. They can kill in two ways, one faster way and one slower. They can either 
utilize the faster way by emptying the contents of cytotoxic granules with the molecules 
perforin and granzyme B into the foreign cell, which initiates a cascade of events finally 
inducing apoptosis. They can also kill trough death receptor-mediated killing, the slower way 
with the ligand FasL. This way involves cross-linking of the cell surface death receptor Fas 
expressed on target cells to the FasL expressed on CTL. Cross-linked Fas/FasL rapidly 
induces assembly of intracellular steps in the cell finally leading to apoptosis [50, 51]. 
T memory cells. Tumor specific CD8+ T cells undergo differentiation to effector T cells in 
the lymph nodes, proliferate and undergo clonal expansion and migrate to the tumor micro 
environment (TME) where they perform their action in killing tumor cells displaying tumor 
associated antigen expressed on the surface. But for long-term immunologic memory a part 
of the effector T cells have to develop into effector memory T cells [60].These cells have the 
capacity to rapidly re-expand to a large number of effector T cells if they are re-exposed to 
the earlier antigen. This gives the immune system a memory of earlier foreign cells. Memory 
T cells can be subtyped into central memory T cells (TCM cells) and effector memory T cells 
(TEM cells). T memory cells could be either CD4+ or CD8+ [50, 51]. 
Regulatory T cells (Tregs) are a subtype of CD4+ T cells and they have a major role in 
protecting the individual from autoimmunity by negatively modulating T cell responses. 
There are two types of Tregs: natural Tregs, which develop in the thymus and induced Tregs, 
which are derived from naïve CD4+ T cells, which  have become activated in the presence of   
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TGF-β (Transforming growth factor beta) [61].TGF- β induces expression of FoxP3, an 
important transcriptional regulator responsible for the development and function of regulatory 
T cells. They negatively regulate the T cell responses either by secreting cytokines IL-10 or 
TGF-β which then inhibit the ability of antigen presenting cells to stimulate T cells, or they 
act more directly on T cells causing apoptosis. Tregs have also been demonstrated to 
negatively affect antitumor immunity both in mouse and in human studies [50, 51]. 
1.2.2.4 Other cells of importance involved in antitumor immunity of relevance to this 
thesis 
MDSC, Myeloid Derived Suppressor Cells are a heterogeneous group of cells that have their 
origin in the myeloid lineage. They were first identified in the middle 1980s as “natural 
suppressor” cells in tumor-free mice where they inhibited T cell proliferation and cytotoxic T 
lymphocytes. In mouse models they are found as myeloid cells expressing high levels of 
CD11b (a myeloid lineage marker) and Gr1 (granulocytic marker). In humans there is 
extensive heterogeneity regarding the expression and level of cell surface markers. The 
phenotype of human MDSC is not as clearly defined as the one in mice, although they can be 
categorized as either monocytic or polymorphonuclear, based on their expression on CD14 
versus CD15. They proliferate during pathological conditions such as chronic infection and 
cancer. They have strong immune suppressive ability especially on CD8+ T cells. They 
perform their suppressive activity through several mechanisms, primarily through the 
metabolism of L-arginine (an amino acid essential for the formation of the T cell receptor and 
thereby activation of the T cell). MDSC produce Arg1 (arginase-1) which degrades L-
arginine thereby suppressing the T cell activation. MDSC also release ROS (Reactive 
Oxygen Species) that block T cell activation. They stimulate inducible NO synthase (iNOS) 
leading to the production of NO resulting in cell toxicity. In addition to all this they act 
through activation of IDO (Indoleamine-pyrrole 2,3-dioxygenase) resulting in tryptophan 
depletion leading to impairment of T cell growth and survival, and through upregulation of 
PD-L1 expression. In addition to direct T cell inhibition MDSCs can also induce and recruit 
T regulatory cells via TGF-β and IL-10 production and CD40-CD40L signaling [62-64]  [50, 
51]. In cancer patients it has been demonstrated that levels of circulating MDSCs correlate 
with clinical cancer stage and metastatic burden and that they are indicator of tumor 
progression [51]. 
NK cells are key players in the antitumor response (especially the innate) and were 
discovered in 1975 by Kiessling and coworkers [65, 66]. They originate from the same 
lymphoid progenitor as B and T cells and can be identified as CD 56+ and CD3- [67]. They 
can provide a fast response to virus infected cells as well as respond to tumor formation and 
they have the unique ability to recognize and kill stressed cells in the absence of antibodies 
and MHC I, which contributes to their rapid response. This ability is also behind how they 
were named, “natural killers” hinting that they do not need activation in order to kill cells that 
are “missing” self, MHC I [68].  There are two main subsets of NK cells; CD56 bright and 
CD56 dim. CD56 bright NK cells make up the majority of NK cells and are found primarily 
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in the bone marrow, secondary lymphoid tissue, liver, and skin and act by releasing cytokines 
[67, 69]. CD56 dim NK cells are found primarily in blood and are CD16 positive, the key 
mediator of ADCC (antibody-dependent cellular cytotoxicity), which characterizes a main 
mechanism how CD56 dim NK cells kill target cells [67, 69]. NK cells perform their effect 
through several mechanisms: cytolytic granule mediated apoptosis, ADCC, activation of 
CTL’s, death receptor ligand, interferon gamma to mention some functions [50, 51]. Earlier it 
was thought that NK cells were involved mostly in the innate immune response, but it has 
become clearer that they as well are involved in the adaptive immune response, which make 
their role in anti-tumor immunity and in cancer therapies more important (ex. PMID: 
29254979). 
1.2.3 Immune response to cancer 
The major role of the immune system is to protect us from invading pathogens, but when 
cancer develops, the pathogen is from within. Cancer cells are very similar to normal 
properly functioning cells so that under normal circumstances they should not be efficiently 
recognized and destroyed by the immune system due to the central tolerance of T cells. The 
transformed cells of tumors express antigens that are not present on normal cells. To the 
immune system, these antigens appear foreign, and their presence causes immune cells to 
attack the transformed tumor cells. The antigens expressed by tumors have several sources 
[70]. Tumor antigens are either TSA (Tumor-specific antigen) or TAA (Tumor-associated 
antigen). Tumor-specific antigens are antigens that only occur in tumor cells [71]. Mutation 
of protooncogenes and tumor suppressors which lead to abnormal protein production are 
drivers of the cause of tumor development and thus those abnormal proteins are the tumor-
specific antigens, for instance abnormal products of Ras and TP53 genes. Mutation of other 
genes unrelated to tumor formation may lead to synthesis of abnormal proteins that are called 
tumor-associated antigens. Tumor-associated antigens are present in healthy cells, but also 
occur in tumor cells and could then be used as tumor markers regarding some tumor types 
[71]. Melanoma is a tumor with a very high mutation rate, increasing the likelihood of 
generation of TAAs. There are certain types of specific melanoma TAAs. They were 
discovered by co-culturing lymphocytes with irradiated tumor cells, identifying the cytotoxic 
T cells that killed tumor cells bearing those TAAs. These melanoma-specific T cells can be 
found circulating in peripheral blood [54]. One of the most common melanoma TAA is 
MART-1 or MelanA, a melanocyte differentiation antigen that is a transmembrane protein 
present in melanocytes of normal skin, retina, nevi, and most melanomas [72-74]. Another 
known melanoma antigen is the cancer-testis antigen NY-ESO-1 [75]. Normal NY-ESO-1 
expression occurs only in testis but its function is still mostly unknown. In melanoma it has 
been found in 20% of invasive tumors and has been associated with increased thickness of 
the primary tumor [75]. Other well-known melanoma TAAs are: MAGE-A3 (Melanoma-
associated antigen 3) a member of the melanoma associated antigen gene family and its 
normal function in healthy cells is unknown. Gp100 (glycoprotein 100 or melanocyte 
protein), a transmembrane protein enriched in melanosomes, the melanin producing 
organelles in the melanocytes, which is involved in melanosome maturation [76].                                                                                                                                         
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When CTLs encounter a cancer cell presenting the matching tumor antigen, the CTLs can 
lyse the cancer cell, resulting in the release of more TAAs and continued loop of destruction 
of the tumor.                                                                                                                                                
When T cells infiltrate the tumor they are known as tumor infiltrating lymphocytes or TILs. 
These tumor specific T cells are also found circulating around in the body and along with 
TILs, their numbers can be used as a prognostic marker for cancer treatment with 






Figure 5. Immune response to cancer: Tumor formation gives rise to antigens (TAA). These are recognized by 
antigen presenting cells. The antigen presenting cells migrate to the lymph nodes where, priming and activation 
of T cells take place, i.e. naïve T cells become activated. After activation, T cells traffic to the periphery and the 




One important role of the immune system is to identify and eliminate tumors. When cancer 
cells are attacked by immune cells the immunogenicity of tumors can change through 
mutations and selection of immune-resistant cancer cells.                                                                
The relation between the tumor cells and the immune system is a dynamic process known as 
immunoediting. It is made up of three phases: elimination, equilibrium, and escape, “three  
E’s of cancer immunoediting” [78]. Simplistically, tumors proceed through each of these 
phases, but in reality it is more likely that transitions between the phases occur in both 
directions. 
 
The elimination phase, also known as immunosurveillance, is the initial phase, in which the 
immune system is able to identify transformed cells and successfully eliminate them. 
During the equilibrium phase, tumor cells through mutagenesis can acquire features 
increasing their resistance to elimination by the immune system. Most of the transformed 
cells are eliminated by the innate and adaptive immune response, but it is no longer possible 
to eradicate them completely. 
Figure 6. Immunoediting: In the elimination phase the immune system, both the innate and the adaptive, recognizes 
and eliminates the tumor cells. During equilibrium phase tumor cells survive the elimination and co-exist with the host 
during strict control with different immune defenses. During escape the tumor have got the ability to circumvent 
immune responses and overcome immunity with different mechanisms.                                                                                                                                                                         
 
 27 
At a certain point, tumor cells are no longer eliminated by the immune system, they 
overcome it and manage to completely escape it. There are several mechanisms that lead to 
escape of cancer cells from the immune system [79], including downregulation or loss of 
expression of classical MHC class I [80], defects in antigen processing, development of a 
tumor microenvironment (TME) with suppressive effect on the immune system [81]. Cells in 
the tumor microenvironment are able to produce cytokines and other mediators which can 
cause apoptosis of activated T lymphocytes [82]. Among the cells that increase in the TME 
during cancer growth are MDSCs, which are found to be increasing in patients with 
metastasized melanoma [83, 84] and they, as mentioned earlier, suppress both CD4+ and 
CD8+ T cells and inhibit T cell production of interferon-gamma (IFN- γ, a very important 
cytokine involved in immune regulation and anti-tumor response). They also facilitate the 
development of other cells that promote tumor progression (macrophages, T regulatory cells). 
It was also shown, by our group, that the frequency of a subgroup of MDSCs (MM-MDSCs; 
CD14+/HLA-DR -/low) in circulation return to physiological if the patient did not have 
active disease or was in regression, indicating a causal correlation between disease status and 
the presence of MDSCs [85]. It has also been shown that the frequency of circulating MDSCs 
in peripheral blood correlate with tumor progression and worse outcome in patients with 
different tumors [86-90]. 
 
1.2.5 Immunogenic cancer 
Malignant melanoma is regarded as the prototype for immunogenic cancer, which means that 
it is affected by and affects the immune system, and this is based on several observations. 
Spontaneous tumor regression was observed already in the 1950s [4] and can be seen both in 
primary melanoma and in advanced disease where it is rare though [91]. The importance of 
TILs (tumor infiltrating lymphocytes) was first described by Clemente et al, showing that 
different infiltration grade of TILs in melanoma was related with survival [92] [93], which 
was also supported by later observations [94][95]. When TILs are enriched and activated they 
are capable of rejecting tumors [96], which is the main principle behind our therapy described 
later in this thesis. There is an increase in the incidence of melanoma in patients receiving 
solid organ transplantation as a result of the immune system being suppressed [97] [98]. 
Melanoma is one of the malignancies with the largest number of mutations [99], leading to 
many tumor antigens being presented, which in turn activates the immune system greatly, and 
is thought to be one of the reasons behind its immunogenicity. Finally, the cancer is 




1.3 SYSTEMIC TREATMENTS OF ADVANCED DISEASE 
In the beginning of the 2000s my relative started to have some symptoms. A pain from one 
side of the thorax appeared which was thought to be related to physical exercise. When the 
pain did not improve x-ray was performed and revealed something in one of the lungs, which 
lead to follow-up, though it was thought that it might be sarcoidosis. Coupled with the pain 
was a tiredness which was explained with having too much work. After almost half a year 
and another couple of x-rays the pulmonary lesion was biopsied and revealed melanoma. By 
then he had deteriorated a lot, experiencing pain and not being able to work. Then it all went 
very fast. After diagnosis of spread melanoma he died in a few months, never making it to 
treatment, which at that time was chemotherapy. This was only around 20 years ago and in 
that period so much has happened to the treatment of advanced disease. 
1.3.1 Historical/earlier systemic treatments of advanced disease 
1.3.1.1 Chemotherapy 
The systemic treatments available in the beginning of the 2000s were limited to 
chemotherapy, such as dacarbazine (which had been approved in the middle of the 1970s 
[100]) and its oral analog temozolomide. For dacarbazine ORR of up to 20% has been 
reported but CRs are rare (about 3–4%), and duration of response is short (median 5–6 
months), with only a few percent of patients experiencing long-term survival [101, 102]. 
Temozolomide has the ability to penetrate the blood brain barrier and demonstrated modest 
antitumor activity [100, 103]. A randomized clinical phase III trial with treatment naïve 
metastatic melanoma patients showed similar median OS for patients treated with 
dacarbazine and temozolomide [104], leading to more use of the oral drug in the clinical 
setting in Sweden. Other treatments were available internationally, most of them being 
immunotherapy and most of them in clinical trials. 
1.3.1.2 Immunotherapy 
History 
Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an 
immune response” and cancer immunotherapy is the use of the immune system to treat 
cancer. Immunotherapy began in 1796 when Edward Jenner produced the first vaccine 
involving immunization with cowpox to prevent smallpox [105]. William Coley (1866-
1936), although not recognized during his lifetime, has thereafter been described and 
recognized as “the father of cancer immunotherapy”. Coley found that patients with cancer 
sometimes developed durable regressions after having an infectious disease [106]. This he 
further investigated by injecting cancer patients with mixtures of live and inactivated 
Streptococcus pyogenes and Serratia marcescens, ‘Coley toxins’. With this method he 
achieved some responses including durable ones, but with the risk of severe infections. The 
lack of a known mechanism of action for ‘Coley’s toxins’ and the risks of deliberately 
infecting cancer patients with pathogenic bacteria contributed to establishing other treatments 
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against cancer [107]. By end of the 19th century Emil von Behring and Shibasaburō Kitasato 
discovered that injecting animals with diphtheria toxin produced blood serum with antitoxins 
to it [108]. In the beginning of the 20th century Paul Ehrlich's (1854-1915) research gave rise 
to the "magic bullet" concept; using antibodies to specifically target a disease. The idea of 
using immunotherapy in cancer, in general, received recognition when Thomas and Burnet 
first proposed the theory of cancer immunosurveillance in 1957 [109]. The strategy of using 
attenuated bacteria to treat malignancies reappeared in 1976 when a trial was conducted to 
test the use of the tuberculosis vaccine Bacille Calmette-Guérin (BCG) to prevent the 
recurrence of non-muscle invasive bladder cancer [110]. BCG therapy was shown to be very 
effective and continues to be used today. The cytokine interleukin-2 (IL-2) was identified and 
purified in 1976 allowing investigators to culture T cells in vitro for the first time [111]. The 
use of IL-2 as an immunotherapeutic drug gained US Food and Drug Administration (FDA) 
approval for metastatic kidney cancer in 1991 and for metastatic melanoma in 1998. In the 
beginning of the 1970s the invention by Jerne, Köhler and Milstein of a method to produce 
monoclonal antibodies laid the ground for antibody therapy in the clinic, and was awarded a 
Nobel Prize in 1984. In the beginning of the 1990s the use of vaccines in the treatment of 
malignancies was developed further, but effective vaccines remained elusive. Thereafter the 
development of melanoma immunotherapies is a success, which will be described further 
below.   
Cytokines 
The connection between melanoma and the immune defense had been considered for some 
time but the benefit of treating melanoma with immune therapy was first realized in the 1980s 
when the cytokines interleukin-2 (IL-2) and interferon-alfa (IFN-α) became available in large 
quantities [112, 113]. Phase II trials with high dose IL-2 showed durable remissions in 16% 
of patients with advanced melanoma and a median duration of response of 8.9 months and as 
long as almost 60 months in the 6% of the patients who were complete responders [114][31]. 
Evidence of long term disease control led to approval of IL-2 by FDA in the 1990s. However, 
the treatment is sometimes associated with severe toxicity such as hemodynamic collapse and 
therefore, along with the fact that no survival benefit has been proven, the use of IL-2 for the 
treatment of advanced melanoma has remained restricted and IL-2 is not yet approved as a 
drug in Sweden. IFN-α also has some measurable effect in melanoma and in small phase I/II 
trials in the 1970’s and 1980’s it’s limited response rate was predominantly seen in patients 
with limited disease burden [113]. Subsequent trials focused on its use in the adjuvant setting.  
The benefit from the treatments with cytokines (IL-2 and IFN-α) was limited and associated 
with toxicity and therefore their role in the clinical setting has been limited. The toxicity of 
these treatments is caused by their mechanism of action, leading to a non-specific stimulation 






Other earlier developed treatments available by the beginning of this century aimed at 
generating a more specific T cell response as tumor vaccination and adoptive cell transfer 
(ACT). 
Vaccination is a preparation of microorganisms administered in order to produce or 
artificially increase immunity to a particular disease. Vaccination can be categorized as 
prophylactic or therapeutic. One of the first recorded instances of vaccination is from China 
circa 1000AD and was made by variolation. This method later spread to Europe and was 
pioneered by Edward Jenner (1749-1823), see above. The idea of vaccination against cancer 
was initiated by Paul Ehrlich (1854-1915), who was the first to propose an immune-tumor 
interaction. He attempted to use weakened tumor cells for immunization in cancer patients, 
but this was no success. William Coley (1866-1936) on the other hand had more but dual 
success with the method of using bacteria to treat malignancies, see above. Further details 
regarding the history of cancer vaccines are described above. In the 1950s the development of 
antitumor vaccines saw the real light when the presence of cancer specific antigens 
potentially inducing an immune response was first observed [115]. Thereafter many clinical 
trials of therapeutic vaccination have focused on melanoma, with the results being mostly 
disappointing and not able to show improved overall survival of melanoma patients, despite 
some promising data in animal models and a few early trials.                            
However, in combination with other treatments vaccination has been shown to be somewhat 
more effective. For instance gp100 and HD (high dose) IL-2 that in a randomised phase III 
trial showed benefit of the combination arm of gp100+HD-IL 2 vs HD IL-2 alone both 
regarding response rate and OS [116]. 
Adoptive cell therapy 
ACT has been proven to induce impressive along with durable responses in patients with 
advanced melanoma. ACT was developed in the late 1980s by Rosenberg and colleagues by 
using the basic technique of purifying TILs from a patient’s fresh tumor, expanding the cells 
in culture ex vivo, and re-infusing them along with a short course of IL-2 [96, 117]. 
  
Figure 7. Adoptive cell therapy, ACT                     ( L. Rehn, 2017) 
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 Early trials reported objective responses in more than 30% of the treated patients [96] [118]. 
Thereafter multiple single-institution studies in patients with metastatic melanoma have 
demonstrated response rates that reach 50% with ACT, as well as complete response rates in 
about 20% of patients, most of which have been durable CRs [119] [120]. Despite the very 
good response rates and durable responses the treatment is not an approved treatment for 
patients with stage IV melanoma, but rather a treatment for a well selected group of patients. 
This treatment method will be described further and reflected upon later in this thesis.  
So by the beginning of this century there were some different treatments available to offer 
patients with MM but none of the approved ones being able to result in prolonged OS. 
1.3.2 The new revolutionizing treatments of advanced disease 
There were, until less than a decade ago, only few treatment strategies to offer patients with 
stage IV melanoma and the median overall survival, as mentioned above was very short. The 
treatments were limited to palliative surgery, radiotherapy and palliative chemotherapy.  I 
recall there was sort of a “hunt” for removing stage IV metastases with surgery or targeted 
radiation if possible. This was because there was a belief that perhaps by removing the 
metastasis not only the symptoms would improve but the survival as well [49] [121], but that 
was debated.       
When I started working at the melanoma unit at Karolinska University Hospital in 2010 I 
remember the clinical trials for advanced melanoma going on by then; one trial with anti-
CTLA-4, ipilimumab and one with the BRAF inhibitor vemurafenib. I remember the 
difficulties I had understanding and differentiating between the different mechanisms of 
action and I guess I was not the only one. However it was fascinating to have something to 
actually offer the patients and a feeling that something big was happening. Since then, 
starting 2011 with the first approval among these new treatments, so much has happened. 
1.3.2.1 Immune Checkpoint Inhibitors; anti-CTLA-4 
In the end of the 1980s, researchers identified cytotoxic T-lymphocyte antigen 4, or CTLA-4, 
a member of the immunoglobulin superfamily and a transmembrane receptor which is 
expressed on activated T lymphocytes [122-124]. It is one of two homologous cell surface 
proteins that counterbalance each other in the activation and inhibition of T cells.                                                                                                                       
CTLA-4 has a stronger affinity to its ligands CD80 and CD86 on antigen presenting cells 
than its counterpart CD28. CD28 transmits a stimulatory signal [125] whereas CTLA-4 
transmits an inhibitory signal [126-128] to T cells. Binding of CTLA-4 to CD80 and CD86 
leads to down-regulation of T-cell activation by induction of T-cell anergy and inhibition of 
IL-2 secretion. This is a protection mechanism, a check-point, preventing the activation of T 
cells from becoming excessive and leading to attack on the organism itself. CTLA4-deficient 
mice suffer from fatal lymphoproliferative disease characterized by multi-organ T cell 
infiltration and die by 3–4 weeks of age, indicating that CTLA4 is an essential negative 
regulator of T cell responses [123, 124]. 
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Allison found that CTLA-4 prevents T cells from attacking tumor cells. In 1996, he also 
showed that antibodies against CTLA-4 allowed the immune system to destroy tumors in 
mice [129]. These preclinical findings led to the clinical development of two humanized anti-
CTLA-4 monoclonal antibodies: ipilimumab and tremelimumab. Eventually also leading to 
the Nobel Prize in medicine in 2018. 
 
 
In early phase clinical trials both agents demonstrated an ability to induce durable clinical 
responses in small subsets of patients with advanced melanoma [130-132]. Ipilimumab was 
thereafter evaluated in two revolutionizing clinical trials published in 2010 [133] and 2011 
[134]. Ipilimumab was the first drug ever to show improved overall survival for metastatic 
melanoma and this lead to FDA approval in 2011 for second line treatment and in 2013 for 
first line treatment. Despite the revolutionizing improvement of OS, only a limited number of 
patients, less than 20%, respond to treatment with ipilimumab, but long-term survival data 
indicates that 20% of patients show evidence of continued durable disease control or response 
5-10 years after starting therapy [135].                                                                                              
There is no pretreatment predictive marker of response or long term survival. The response to 
the treatment may also occur late, sometimes up to more than 6 months after the end of the 
treatment schedule and a late response can be preceded by an early progression (often in the 
first 6-12 weeks of treatment), so called pseudo-progression, of the disease, which was 
reported to occur in about 10% of treated patients [136, 137]. This together makes the 
treatment rather difficult to handle in a real life clinical setting and not suitable for all patients 
with generalized melanoma, especially when used as second or third line treatment. The ideal 
patient for treatment with ipilimumab has good performance status, limited slow progressing 
Figure  8. CTLA-4 and CTLA-4 antibodies: When T cell activation takes place CTLA-4 gets activated and acts as a 
break, in order to protect the individual from too excessive activation of T cells and thereby autoimmune reactions. 
CTLA-4 has a greater affinity for B7 than CD28, which makes this protection mechanism workable. Anti-CTLA-4 
antibodies block CTLA-4 and thereby “block” the break and consequently activate the T cell response. 
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disease and no lesions threatening vital organs and the patient should be able to tolerate a 
pseudo-progression. 
The treatment-related specific toxicities are of autoimmune kind and they are frequent. More 
than 70% of the treated patients will experience side-effects which may be severe and in 
some cases potentially fatal if not discovered in time and treated with high-dose cortisone. 
One of the most common toxicities with ipilimumab treatment is colitis which usually occurs 
during the first 1-2 months of treatment and can rather easily be managed if recognized in 
time. The more unusual toxicities of endocrine and neurological kind more often occur later 
after the treatment initiation and may be more difficult to treat. 
Taken together, the fact that only few patients respond to the treatment, the difficulty to select 
the right patients and the frequent and sometimes severe side-effects make the treatment, 
although it being revolutionizing in its kind, difficult to use and monitor in the clinical 
setting. 
1.3.2.2 Targeted therapy, inhibitors of the MAP kinase pathway 
Another group of systemic treatment, oral kinase inhibitors was in many ways much easier to 
manage in the real life clinical setting and the first of these drugs was also approved in 2011. 
A precondition for this type of treatment to function is that the tumor harbors a BRAFV600 
mutation, which is the case in about 40-60% of cutaneous melanomas. This mutation causes 
hyper activation of the MAPK pathway leading to increased cell division and tumor growth. 
Figure  9. MAPK pathway: Normal activation of the pathway occurs when extracellular growth factors bind to the 
receptor, then resulting in downstream activation of the pathway, eventually leading to normal cell proliferation and 
survival. Mutations of BRAF result in constitutive activation of the pathway without any upstream activation through 
growth factors. This causes excessive cell proliferation and survival. With the use of BRAF and MEK inhibitors, the 
activation gets halted in several steps in the excessive down-stream activation. 
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The approval of the first BRAF inhibitor, vemurafenib was based on a phase II trial [138] 
showing that overall response rate for patients with advanced melanoma was more than 50% 
and a phase III trial comparing vemurafenib with dacarbazine, showing much better response 
rate (50% vs 5%) and both improved progression free survival and overall survival for the 
vemurafenib cohort [139, 140]. After that another BRAF inhibitor, dabrafenib was approved, 
showing a similar effect in a phase III trial [141], but with different and more manageable 
toxicity profile.  
When first using BRAF inhibitors it was very compelling to be able to offer them to patients 
since the response rate was high, the symptoms could improve already after a short time and 
the performance status of the patients as well could improve. From being severely ill from a 
deadly disease, the patients could become almost free of symptoms and sort of get his or her 
life back, which was also very satisfying for us clinicians being a bit like magicians. 
Unfortunately, then comes disease progression, due to acquired resistance through 
reactivation of the MAPK pathway [142, 143].With BRAF inhibitors alone it came already 
after about 6-8 months and often it came very rapidly and the progression was frequently 
stormy. The hope that slowly had been built up was harshly destroyed again. One could really 
say that there was a shadow around the initial response, since you sort of knew that the 
progression eventually would come. That, coupled with the not so pleasant toxicity of the 
single drug use of BRAF inhibitors, especially vemurafenib (rash, photo-sensitivity, 
arthralgias, hair-loss, and squamous cell carcinoma (SCC)-like lesions) [139] made the 
clinical use of single agents somewhat dubious. The situation became better when the 
combination of BRAF and MEK inhibitors was approved in 2015. The approval was based 
on several trials showing better response rates, better progression free survival, better overall 
survival and improved toxicity profile compared to treatment with BRAF inhibitor alone 
[144-147]. Using this combination in the clinical setting was easier, since the toxicity was 
milder, the duration of response more satisfying and when progression came, perhaps it 
seemed like it did not appear as rapidly as with single use. Although patients in most need for 
the rapid response of the targeted therapy; those with large tumor burden, many sites of 
metastases, high LDH and symptoms from their disease, still progressed faster than patients 
with a more favorable situation, indicating that low disease burden at baseline can be 
prognostic for a long term benefit [148, 149].  
Targeted therapy was more manageable in the clinical setting than anti-CTLA-4, but when 
another type of check-point blockade was introduced the arena changed again. 
1.3.2.3 Immune Checkpoint Inhibitors; anti-PD-1 
In the early 1990s, Tasuko Honjo identified a molecule expressed in dying T cells, which was 
named programmed death 1, or PD-1 and which was recognized as another regulator with 
negative effect on T cells. Programmed death-1 (PD-1) is a checkpoint receptor that also 
belongs to the CD28/CTLA4 receptor family [150] [151] [152]. PD-1 binds to two known 
ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) which are widely expressed in a variety of 
tissues [153, 154]. When PD-1 binds to PD-L1, it negatively regulates T cell functions [151] 
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[152] [153]. PD-L1 is expressed in many tumors, including melanoma [155, 156]. PD-1/PD-
L1 interactions have been studied in animal models, as well as in vitro, and the complex has 
been shown to inhibit the effector functions of tumor-specific CD8+ T cells, thereby 
contributing to tumor-induced immunosuppression with tumor resistance to cytotoxic T cell 
responses [155-157].  
Unlike CTLA-4, which is primarily involved in immune cell activation and generation of 
early responses, the PD-1 system is important in immune escape at the point of CTL 
mediated cell-killing, and seems primarily designed to limit overresponse to infection and 
prevent autoimmunity in the periphery [151, 158,159]. In contrast to the rapidly appearing 
systemic autoimmunity observed in CTLA-4-deficient mice, PD-1 deficiency results in 
delayed-onset, organ-specific autoimmunity. Depending on their genetic background these 
mice within some months develop autoimmune symptoms such as lupus-like syndromes and 
autoimmune cardiomyopathy syndromes [160-162]. This suggests that PD-1 might function 
more as an inhibitor of lymphocyte responses in the periphery. Chronic antigen exposure 
from viral antigens has been observed to induce PD-1 expression and create a state of anergy, 
or immune non-responsiveness in antigen-specific T-cells. A similar upregulation of PD-
L1/L2 is observed on tumor cells [82]. The inhibition of T cell function through the activity 
of PD-1 is therefore a critical therapeutic target for the activation of T cells. This rationale has 
led to the development of monoclonal antibodies that block the activity of PD-1 receptors. 
These antibodies block the PD-1 receptors on T cells, making them unable to respond to PD-
L1 or PD-L2 expressed on tumor cells. This, in turn, leads to the activation of T-cell activity 
and a decrease in tumor growth. 
Figure 10.  PD-1 check-point acting in the periphery and anti-PD-1 antibodies. 
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Soon after the development of ipilimumab, data from early trials describing the clinical 
activity of the anti-PD-1 antibodies emerged with response rates around 30% and with a 
much more favorable adverse event profile [163-165]. 
Pembrolizumab was the first anti-PD1 antibody to be approved by the FDA for the treatment 
of metastatic melanoma. Three trials led to the approval of pembrolizumab: the phase I trial 
Keynote-001, the phase II trial Keynote-002 and the phase III trial Keynote-006 [166-168]. It 
was initially approved for the treatment of metastatic melanoma after progression on 
ipilimumab.                                                                                                                                            
The second anti-PD1 antibody to be approved was nivolumab and the approval was based on 
two trials, CheckMate-066 [169] and CheckMate-037 [170, 171] and as with pembrolizumab 
it was initially approved to be used in the setting of advanced melanoma progressing on 
ipilimumab.                                                                                                                                         
The real effect on overall survival cannot be evaluated in the above mentioned trials as none 
of the trials was designed to evaluate that endpoint. Thus more long-term follow up has 
shown positive results regarding response rate, response duration and overall survival rate at 
both 3 years and 5 years for patients treated with pembrolizumab and nivolumab [168, 172-
174]. Cross study comparisons of homogeneous groups of patients treated with 
pembrolizumab or nivolumab monotherapy have similar results regarding clinical endpoints 
and adverse event rates [175]. Their efficacy has been shown both for treatment naïve 
patients and previously treated patients, which the above mentioned trials suggest. 
Anti-PD1 antibodies moved very fast from initially being used in the last line setting to 
become established as frontline therapy for metastatic melanoma, because of their higher 
response rates, more tolerable toxicity profile, and fewer grade III or IV adverse events (AEs) 
than ipilimumab. PD-1 inhibitors are overall better tolerated than ipilimumab, and even 
though fatigue is a common problem (16-24%), irAEs occur less frequently and are  more 
often of lesser severity (<12% grade 3 or higher events) [176].The spectrum or organs 
involved is similar to ipilimumab, although there is a higher incidence of pneumonitis and 
thyroid dysfunction. 
Despite the success in the clinical setting, with the much improved response and toxicity 
profile, there are a still only a limited number of patients that benefit from treatment, albeit 
they could be long-term responders or even cured and treatment could be stopped. With the 
toxicity profile being as mild, it is easier to be tempted to use these drugs even though the 
clinical parameters indicate that there is a risk of the patient not benefitting; large tumor 
burden, elevated LDH, but perhaps still rather good performance status. With ipilimumab it 
was in some sense easier to make the decision that clinical benefit most certainly would not 
happen, but with anti-PD1 it is easier “to try any way” which could be considered from both a 




1.3.2.4 Combination of Immune Checkpoint Inhibitors; anti-CTLA-4 and anti-PD-1 
CTLA-4 and anti-PD-1 perform their action in different parts of the immune activation 
cascade. CTLA-4 is thought to affect the immune priming phase by regulating T-cell 
proliferation early, primarily in lymph nodes, whereas PD-1 suppresses T cells later during 
the effector phase, primarily in the peripheral tissues, or in the tumor bed during antitumor 
response [158]. 
 
This difference lead to the use of the combination of anti-CTLA-4 and anti-PD-1 in order to 
achieve better efficacy, which was also shown in the pivotal trial check-mate 067, where a 
much higher rate of response and better PFS was seen in patients treated with the 
combination [177, 178]. This trial also found that patients with tumors lacking PD-L1 
expression had an overall survival benefit [177, 178]. The data have recently been updated 
regarding 5-year overall survival showing a slight, but not statistically significant better 
overall survival for the combination as compared to anti-PD-1 single use [179].                                                               
However, the better efficacy really comes with a high price for many of the patients with the 
toxicity being much higher for the combination compared to single use of both anti-CTLA-4 
and anti-PD-1, with grade 3-4 toxicity in about 55% of patients in the combination arm in the 
check-mate 067 trial. Thirty-six percent of patients in the combination arm discontinued 
treatment, but among those, 70% maintained the achieved therapeutic response.                  
The most common AEs of any grade with the combination were gastrointestinal toxicity, 
asthenia, and pruritus, followed by rash, loss of appetite, nausea, and pyrexia [178].            
The more severe toxicity can be treated with high dose corticosteroids or TNF-alfa inhibitors. 
Figure 11. Dual treatment with both anti-CTLA-4 and anti-PD-1 antibodies. 
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Despite that, severe toxicities may lead to durable hospitalizations and sequels which take 
very long to recover from and thereby decreased quality of life. The severe toxicity is of 
autoimmune type and can affect most organ systems. It seems though, form a pure clinical 
perspective, that the immune related toxicities sort of mimic an original autoimmune 
spectrum of disorders and that they are more difficult to diagnose and to treat than the 
original autoimmune disorders.                                                                                                                      
It is easy to be impressed by the very, very good response rates and not to think so much of 
the AE.                                                                                                                                                 
The treatment really is not a true savior and one must ask oneself if it is better to have 
decreasing tumors but suffer with sequels form toxicity that makes one’s life very deprived of 
quality. It makes me think of “horror autotoxicus” and that Ehrlich did not think that the 
immune system could attack the organisms own tissue, which was later shown by his student 
Witebsky that it could [180]. It is my clinical feeling that can arise when meeting the patients 
suffering from severe complicated toxicity caused by the combination therapy, “horror 
autotoxicus”.   
This harsh clinical setting has resulted in reconsidering of combination immunotherapy and 
to trials where the dosage of ipilimumab and nivolumab is altered with higher dose of 
nivolumab at 3 mg/kg and a lower dose of ipilimumab at 1 mg/kg. For instance Keynote-029 
showing preliminary results with high activity (PFS of 70% at 6 months), similar to that 
observed with the initial regimen, but with 25% immune-related grade 3-4 AEs [181]. 
Another trial, check-mate 511 with the dosage of nivolumab at 3 mg/kg and ipilimumab at 1 
mg /kg showed correlative effect on treatment response, progression free-and total survival as 
with the initial dosing of nivolumab 1mg/kg and ipilimumab 3mg/kg, but significantly lower 
frequency of serious (grade 3-5) immune related  toxicity [182]. This regimen has sought its 
way more and more into the clinical setting, which is an advantage for the patients and a 
relief to us prescribers. This combination has also been tried in another setting; in different 
treatment lines to more heavily treated patients with some good preliminary results [183].  
The sequence of immune therapy has also been considered. Is it more favorable to treat with 
anti-CTLA-4 before anti-PD-1 or vice versa? Anti-CTLA-4 agents can upregulate PD-L1 
expression, potentially enhancing the action of a subsequent PD1/PD-L1 inhibition in the 
tumor microenvironment [184]. Some patients with advanced disease are in the need of a 
rapid tumor reduction. CTLA-4 activation, as mentioned above, mediates an earlier phase in 
the immune response than PD-1. To induce an antitumor response, ipilimumab has to activate 
T cells in the lymph nodes. Thereafter these T cells could migrate to the tumor site, while 
anti-PD-1 antibodies can activate lymphocytes directly in tumor microenvironment. This has 
a clinical implication, as ipilimumab´s activity occurs slower than that of anti-PD-1 
antibodies. Thus initial administration of anti-PD1 antibodies could lead to rapid responses, 
and sequential ipilimumab could result in enhanced antitumor activity. The efficacy of 
sequential treatment has, as mentioned above, been tried in different settings [185-189], but 
neither of them so far being able to offer a consensus for the clinical setting. There is quite 
some debate in the field regarding the most favorable way to combine anti-CTLA-4 and anti-
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PD1; combination therapy or sequential. With the combination it could potentially lead to 
more potent and perhaps more durable effect or even cure, but with higher risk of toxicity 
risking quality of life. With sequential treatment the potential risk of severe toxicity lowers 
but with the price of reduced potential of efficacy? These are questions we have to get more 
involved in and also to raise these questions with the patients. What is important to them and 
what are they prepared to offer and to risk for the potential longer time of tumor freedom? 
1.3.2.5 Adjuvant treatment with Immune Checkpoint Inhibitors for advanced disease 
Since 2017 immunotherapy with anti-PD1, both nivolumab and pembrolizumab are approved 
also in the adjuvant setting regarding stage III-IV melanoma that is surgically radical. Their 
approval was based on improved and prolonged RFS (Relapse free survival). Nivolumab in 
the adjuvant setting resulted improved RFS compared to ipilimumab with lower toxicities 
[190]. Pembrolizumab was shown to result in longer RFS compared to placebo and with no 
new toxicities compared to other pembrolizumab monotherapy trials [191]. 
While earlier the care of melanoma patients was mostly about active follow-up of stage II and 
III patients and treating stage IV patients with active disease, the care nowadays has shifted a 
lot to being more about offering treatment in the adjuvant setting. This is a total new way for 
us to deal with these patients. Earlier there were many questions about why there was no 
treatment given to reduce the risk of recurrence. Now there actually are several that reduce 
the risk of recurrence, but it is not certain they offer prolonged survival and they could cause 
durable toxicity. The patients are mostly positive to receiving adjuvant treatment though I 
suppose they feel that is more secure than just to wait and see. But we have to bear in mind 
that right now we do not know if our adjuvant treatments offer them prolonged survival and 
this we have to be humble to. Especially, as the treatments could mean toxicity resulting in 
affected quality of life. 
1.3.3 Resistance to check-point inhibition 
Despite the new drugs and the new strategies and their success in providing long-term 
efficacy and even cure for a small group of patients, not all patients are suitable for immune 
therapy as it is today. Around 35-60% of patients treated with anti-PD-1 respond to treatment 
according to RECIST criteria, but that also means that around 40-60% will not experience 
response and about 45% of patients experiencing response will eventually progress [167, 177, 
192].                                                                                                                                             
So who are the patients suitable for immune therapy? Why do some not respond at all and 
why do some respond initially, even during a long time and then progress?                                     
In the clinical setting we have through experience learned that a patient with large tumor 
burden, rapid disease progression, elevated LDH, affected performance status or symptoms 
from CNS metastases is not ideal for immune therapy. 
But what are the biological factors involved in response and lack of response?                                                                                                     
Analysis of clinical data have helped distinguish between the main groups of patients and 
their pattern of response or the lack of thereof. The limited group that respond initially and 
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continue to respond (responders) (Although the responders could be difficult to define and 
sort out, as the response could be in a heterogeneous manner, that we have not been 
accustomed to). Despite that, patients benefiting from ICI seem to do so for a durable time, 
regardless of the heterogeneity of exact response categorization [193]). Those that fail to ever 
respond (innate resistance), and those that initially respond but eventually develop disease 
progression (acquired resistance) [194-196]. This way of describing responders is also one 
way to classify the type of resistance (innate or primary and required).  
Resistance can also be classified as intrinsic or extrinsic to tumor cells. Intrinsic resistance is 
seen when cancer cells alter processes that are related to immune recognition, cell signaling, 
gene expression, and DNA damage response. Extrinsic resistance occur external to tumor 
cells throughout the T-cell activation process [197].  
The exact mechanisms behind resistance to ICI and the different types of resistance are not 
fully understood, although the field is continuously progressing. To a large extent this 
depends on the fact that the exact mechanisms behind response and long term benefit from 
ICI are not either fully understood. Therefore it is useful to keep the known mechanisms of 
immune response to tumor in mind in order to understand potential mechanisms of resistance 
as many of the important steps of activation of immune response to tumor can be inhibited, 
blocked, bypassed, upregulated or hi-jacked by the tumor, contributing to resistance. 
There are many theories related to the exact mechanisms of response to ICI. After having 
tried to get at grasp on this large, continuous expanding field I have understood that it is 
generally accepted that in order to achieve a successful antitumor response to ICI, a 
reactivation and clonal expansion of antigen experienced T cells in the TME is necessary 
[193, 196, 198]. In other words; optimal antigen presentation, proper recognition of these by 
TCR, signal one in T cell activation, signal two in T cell activation, expansion of tumor 
specific of CD8+ T cells that differentiate into effector T cells that migrate to TME and kill 
tumor cells [193, 198, 199]. For long-term immunologic memory, a part of the effector T 
cells have to develop into memory T cells, presumably contributing to durable responses of 
the disease [60, 193, 200, 201]. 
As this thesis is based on clinical experience and clinical studies, some mechanisms of 
resistance will be briefly and superficially reflected upon related to the clinical setting 
concerning primary/innate and acquired and in relation to melanoma resistance to ICI. 
1.3.3.1 Primary/innate resistance 
The patients not responding to ICI already upfront could have a disease with clinical features 
mentioned above and some of the molecular mechanisms will here be mentioned and they 
can appear at any level of the immune response to tumor discussed above or be of intrinsic or 
extrinsic kind.  
Some tumors lack sufficient antigen presentation by the immune system [202] or do not 
present antigens that can be recognized as foreign [195]. The procedure to sort out normal 
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cells from tumor cells depends on T cells being able to recognize certain tumor associated 
antigens (TAA). Tumor immune evasion by TAA negative cells has been reported in 
melanoma patients relapsing after vaccine therapy [203].                                                                                          
Mutational load is a feature correlated with anti-tumor immune response and response to ICI, 
presumably by enhanced neoantigen formation [199, 204]. Thus tumor types harboring high 
levels of mutations (e.g., melanoma, lung, and bladder) are among those with highest 
response rates to ICI [205]. In advanced melanoma, an increased mutational burden is also 
associated with elevated PD-L1 expression [206]. This has been associated with response to 
ICI in several studies [207, 208].                                                                                                                                       
To be able to properly activate T cells DCs go through maturation, where they for instance 
increase their expression of co-stimulatory molecules [209]. In melanoma it has been shown 
that the density of DCs correlates with activated T cells [210].      
When the T cells have become activated they travel to tumor sites and hopefully infiltrate 
tumors to eradicate them. There are a number of ways tumors can prevent this from 
happening and thereby contributing to resistance. They can for instance downregulate 
chemokines necessary for attraction of T cells to the tumor, upregulate endothelin B receptor, 
affect the T cell homing, adhesion and migration. They are also able to overexpress VEGF 
(Vascular endothelial growth factor) that negatively affects T cell adhesion to endothelium, 
resulting in decreased infiltration of T cells into tumors [211], which has been associated with 
increased growth and progression in melanoma. It has also been shown that tumor biopsies 
from non-responders to ICI had increased expression of VEGF compared to responders 
[212].                                                                                                                                     
When T cells have become properly activated and infiltrate the tumor they can also be 
stopped by immunosuppressive cells within the tumor microenvironment. These cells use 
several mechanisms to hinder the T cells. Upregulation of PD-L1 which leads to decreased 
function of cytotoxic T cells thereby helping tumors to escape. Induction of IDO, that via its 
degradation of tryptophane plays a role in the negative regulation and suppression of T cell 
function. T cells go into arrest when tryptophane is depleted [213]. An association has also 
been shown between IDO and recruitment of and increased infiltration of MDSCs as well as 
CD4+FOXP3+ Tregs, which both are known to suppress T cells [214]. Clinical trials have 
also shown that increased presence of MDSCs in TME was correlated to worse outcome in 
patients treated with ICI [215]. Upregulation of T regulatory cells leads to further suppression 
of T cells and as mentioned earlier Tregs suppress T cells through a number of ways, for 
instance directly through cell-cell contact or through inhibitory cytokines. Infiltration of 
Tregs has been observed in many cancer types, also among TILs in metastatic melanoma 
lesions, suggesting their immunosuppressive activity [216]. A correlation between decreased 
Tregs and increased tumor control and improved survival outcome in patients treated with 
ipilimumab was shown already several years ago [217].                                                                                            
Mutations in the molecules JAK1/2 (described below more in detail) have also been linked to 
primary resistance to ICI in melanoma [218]. 
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1.3.3.2 Acquired resistance 
Clinically, acquired resistance can occur in many ways. It can develop after only a short 
period of initial response or gradually via progression of initially only a few lesions to 
documented progression. It can also develop after an even longer period when a previous 
responder relapses, causing restart of ICI and not responding to it again.   
Some molecular features involved in this and in relation to melanoma treatment with ICI will 
be reflected upon in the following. Many of the mechanisms underlying primary resistance 
are also thought to be involved in the development of acquired resistance. They can occur in 
analogy with what was discussed above, at different levels of the activation of immune 
response to tumors.  
At the level of antigen presentation and activation of T cells a number of events can occur 
that could contribute to acquired resistance, for instance mechanisms leading to loss of 
expression of neo-antigens or loss in beta-2-microglobulin expression causing failure in 
MHC function, leading to a decrease in recognition by T cells [219]. One study of patients 
with melanoma found truncating mutations in ß2- microglobulin, leading to loss of MHC-I 
expression and acquired resistance to ICI [220].  
At the level of individual cells in the TME other mechanisms contributing to resistance can 
happen. IFN-γ signaling, through the JAK/STAT family receptors, upregulates expression of 
MHC class I, contributing to enhanced antigen presentation. Mutations in JAK 1/2 have been 
linked to acquired resistance to ICI treatment in melanoma, as these mutations in tumor cells 
lead to decreased sensitivity to IFN-γ, thereby preventing IFN-γ induced cell growth arrest 
[220]. IFN-γ also functions within a negative-feedback loop to increase expression of PD-L1 
[221] and upregulation of PD-L1 on tumor cells limits the function of T cells. 
Overexpression of other immune check-points than CTLA-4 and PD-1 has been linked to 
resistance to ICI. In several studies a correlation between upregulation of for instance TIM-3, 
LAG-3 and acquired resistance to ICI has been observed (not only in melanoma) [222-224].  
Other immune check-points continue to be discovered, for instance including B and T 
lymphocyte attenuator (BTLA), T-cell immune-receptor tyrosine-based inhibition motif 
domain (TIGIT), and V-domain immunoglobulin-containing suppressor of T-cell activation 
(VISTA). Co-expression of several immune check-points has been associated with an 
exhausted state of T cells and thereby perhaps a poor response to therapy. These check-points 
need to be further explored. 
1.3.4 Cold and hot tumors 
A way of describing and understanding the behavior of tumors and thereby how to treat them 
and make them more prone to respond to therapy, especially immunotherapy, is categorizing 
them as cold and hot tumors.                                                                                                       
A “cold” tumor is characterized by a lack of immune cell infiltration in the tumor-tissue and it 
is surrounded by a microenvironment rich in immunosuppressive cells such as T regulatory 
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cells and MDSCs and poor in NK cells, CD8+ T cells and functional APC [225].                         
A “hot” tumor or an inflamed tumor has a high infiltration of immunocompetent cells such as 
CD8+ T cells and NK cells and has high numbers of functional APCs [225].                             
There are groups of tumors that are generally considered to be “hot” tumors and they include 
melanoma, kidney cancer, bladder cancer, head and neck cancers, liver cancer and non-small 
lung cancer. In contrast groups of tumors considered to be “cold” tumors are ovarian cancer, 
prostate cancer, pancreatic cancer and glioblastomas.                                                            
Within a tumor group generally known to be “hot”, there is of course heterogeneity and not 
all tumors within that group are “hot”.                                                                                          
Tumor groups considered as “hot” are more prone to respond to immunotherapy, especially 
anti-PD-1 therapy. 
1.3.5 New treatment combinations and treatment sequence 
The resistance to checkpoint inhibitors, either primary or acquired, has led to the 
development of combinations of checkpoint inhibitors and other treatment strategies in order 
to overcome the resistance. In addition to that, these combinations have the underlying intent 
to convert a cold tumor into a hot one, in order to make the disease more prone to respond to 
immune therapy.                                                                                                                                  
There are almost an uncountable amount of trials going on with different combinations of 
checkpoint blockade and other treatment strategies. Most of them have the basis and rationale 
in the resistance mechanisms mentioned above, and address how new combinations can help 
overcome both primary and secondary resistance. Some of them have sought their way to the 
clinic and some of them have become a part of the daily clinical work nowadays also 
meaning treating patients in clinical trials with new combinations. From being almost naïve 
to trials as there where not so many including melanoma patients back in the “old” days (like 
15 years ago.), melanoma oncologists have become wiser at including patients in new trials 
with agents one hardly can pronounce or even less fully understand the theory behind. 
Luckily there is often information for the patients in the informed consent that one could lean 
on.                                                                                                                                                         
There are several modalities trying to overcome resistance and by that trying to create better 
response rates and better duration of response [197]. Combination of different ICI, ICI and 
chemotherapy, ICI and different types of radiotherapy, ICI and targeted therapies (with one 
combination recently (july 2020) approved by FDA; atezolizumab in combination with 
cobimetinib and vemurafenib for patients with unresectable or metastasized BRAF V600 
mutation positive melanoma), ICI and macrophage/(TAM) inhibitors, ICI and 
cytokine/chemokine inhibitors, ICI and epigenetic modulators, ICI and immune-stimulatory 
agents, ICI and oncolytic viruses, ICI and cancer vaccines or ACT which together will be 
dealt with further.                                                                                                                                             
In this bushy landscape of trials and potential actions and efficacy it is easy to get lost, both 
for us clinicians and for the patients. It is therefore of greater and greater importance to keep 





The necessity to find biomarkers, especially in relation to ICI, has by others been described in 
a three-fold way, which I agree to and find wise: they may allow for a more personalized 
treatment, they may lead to minimizing toxicity without positive treatment outcome and 
finally they may save costs and resources. During the past years when the use of ICI has 
developed, several biomarkers have been identified and studied, but so far there is no 
consensus and no established biomarkers to rely fully on when deciding regarding therapy 
and the sequence thereof. 
A biomarker is a cellular, biochemical, and/or molecular (genetic and epigenetic) 
characteristic that can be objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention [226]. They can be prognostic which offer insight to overall outcome of a 
patient, predictive that could offer insight to the probability of a response of a patient to a 
particular treatment or pharmacodynamic whose level changes in response to an exposure to 
a medical product or an environmental agent. Parameters used as biomarkers can be derived 
from blood, tumor tissue or be related to clinical or host factors or toxicity and in the case of 
melanoma related to irAEs. 
1.3.6.1 Prognostic biomarkers 
In primary melanoma, the most known and used prognostic biomarker is the thickness of the 
primary lesion measured in mm (Breslow) which is a part of the staging system AJCC and 
TNM.  
The earliest and most used and well established clinical prognostic biomarker for spread 
disease in melanoma is LDH. Its role is to catalyze pyruvate to lactate and by that indicating 
cancer metabolic activity and increased glucose uptake by tumor cells. It is by that an 
unspecific marker indicating high metabolism and tumor burden in a variety of malignancies, 
including melanoma [227, 228]. It was shown by Balch et al in the beginning of the 2000’s to 
be an independent predictor of overall survival in over 8000 patients with advanced disease. 
The 1-year survival rate in that cohort for patients with normal LDH was 65%, whereas only 
32% for patients with elevated LDH [33]. LDH is used in the clinical setting before deciding 
if and what systemic therapy to choose and thereafter to follow possible treatment response or 
disease development.                                                                                                                        
LDH has also been shown to be a negative prognostic marker, regardless of treatment given, 
including the new modern treatments [148, 229-232]. Regarding ICI, LDH is in several large 
trials shown to be an indicator of overall outcome. For instance in the three-armed trial with 
ipilimumab/nivolumab vs nivolumab vs ipilimumab outcomes varied markedly by baseline 
serum LDH value [178]. 
Burden of metastatic disease has also been used when considering severity of disease and 
likelihood to benefit from treatment. For instance, in the trial mentioned above with 
ipilimumab/nivolumab versus nivolumab versus ipilimumab a subgroup analysis was 
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performed regarding burden of disease looking at both the summed measure of lesions at 
baseline and number of metastatic sites. It was shown that both the summed measure of 
lesions at baseline and number of metastatic sites correlated with outcome [178].   
1.3.6.2 Predictive biomarkers                                         
When it comes to predictive biomarkers regarding the new modern treatments, the research 
field is, as with new treatment combinations, almost flooding over. There have been some 
indications of biomarkers that could be indicting treatment response, but none of them really 
yet seeking its way into the clinical setting acting as useful markers of response to ICI, 
optimal regimen selection or development of irAEs.                                                                             
The most famous, well-characterized and clinically used predictive biomarker in patients with 
metastatic melanoma is the presence of a BRAFV600 mutation, which is highly predictive for 
response to BRAF ± MEK inhibition. 
When considering predictive biomarkers in regards to ICI they are often categorized as: 
tissue/tumor, tumor microenvironment, blood or clinical. 
Tumor intrinsic parameters associated with response to ICI 
Tumor size at baseline, at start of treatment with ICI, has been linked to response rate and 
OS, where it is more favorable to have lesser baseline tumor size [233, 234].                                                                                                   
A higher TMB has been linked to better response to ICI [235] and it is hypothesized that it is 
due to increasing numbers of mutations correlating with increased neoantigen generation, 
which then increases the likelihood of generating immunogenic peptides that can be attacked 
by T cells.                                                                                                                                              
Mismatch repair (MMR) is a process by which cells identify and correct mismatched DNA 
bases. Tumors deficient in this process (dMMR) consequently have an increased mutational 
burden which could be identified by the presence of microsatellite instability (MSI). MSI-
high (MSI-h) has been linked to higher anti-tumor response upon treatment with ICI [236, 
237]. Although it is uncertain whether it is MSI-h itself that could be linked to response, or if 
it is the consequence of MSI-h, high mutational burden or neoantigen formation that is the 
actual link.     
Tumor microenvironment parameters associated with response to ICI   
PD-L1 is a ligand of PD-1 and serves an inhibitory signal in PD-1 expressing cells. By that, 
the expression of PD-L1 (assessed by IHC staining) in tumor environment would have been 
an ideal biomarker and has been speculated to correlate with response in ICI treated patients. 
But the use of different PD-L1 IHC antibodies with non-homogenous cut-off values among 
the studies have led to contrasting results, making it not totally reliable as a biomarker so far 
[169, 177]. Although it continues to be explored as it theoretically would have been a good 
biomarker and as it still might offer important information considering the circumstances in 
which it has been used, as mentioned above.                                                                                                                                              
Higher numbers of tumor infiltrating lymphocytes (TILs) have generally been a favorable 
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prognostic factor in many types of cancers, such as melanoma and colorectal cancer [238, 
239]. The presence of CD8+ TILs at the invasive margin have been demonstrated to correlate 
with better tumor response and an increase in CD8+ TILs from baseline to post-treatment 
biopsy, has also been demonstrated to associate with tumor regression in melanoma patients 
treated with pembrolizumab [240].                                                                                                  
Loss of IFN-γ pathway genes has been associated with innate resistance to anti-CTLA-4 
therapy and worse overall survival [241]. Melanoma patients with higher expression of IFN-γ 
and IFN-γ inducible genes before start of treatment were seen to be more likely to respond to 
anti-PD-L1 therapy [242]. Similarly, other studies have looked at the consequences of 
aberrations in downstream IFN-γ signaling, such as JAK-STAT.                                                                                                          
MHC class I and II protein complexes are responsible for tumor antigen presentation leading 
to the recognition by T cells (MHC-I: CD8+ and MHC-II: CD4+) and by that they are an 
important step of antitumor immune response. High MHC-II expression has been positively 
correlated with improved response rate as well as prolonged overall survival in patients 
treated with anti-PD-1 [243]. Low MHC-I expression on the other hand has been correlated 
with increased likelihood of progressive disease in ipilimumab treated patients [244].                         
Increased expression of ICOS, a co-stimulating molecule expressed by activated conventional 
and regulatory T cells, on CD4+ T cells that was sustained for more than 12 weeks after start 
of ipilimumab treatment has been reported to correlate with improved survival in patients 
treated with that particular ICI [245]. An increase in CD4+ ICOS+ T cells already after the 
first cycle with ipilimumab (remaining for the whole treatment course) has also been reported 
by our group, although we could not find any relation to survival [246].                                                                                                                               
Finally, tumor suppressive factors and cells in the stroma as IDO, MDSC’s and Tregs have 
also (as mentioned above in relation to resistance) been linked to outcome in patients treated 
with ICI [247]. 
Blood parameters associated with response to ICI 
As mentioned above LDH is a well-established prognostic biomarker. It has also been shown 
to be a predictor of response. One trial that showed an association of elevated baseline LDH 
level with worse OS in anti-PD-1 treated patients also showed that change in LDH level 
during treatment was significantly associated with response. In the patients with an elevated 
baseline LDH level, those with a partial response had a mean reduction of 27, 3% in their 
serum LDH level compared to those with progressive disease who had a mean increase of 
39% in serum LDH level [248].                                                                                                                                  
Relative lymphocyte count (RLC) at baseline has been associated with less response in 
ipilimumab treated patients. Patients with RLC <10, 5% had worse survival than those with 
RLC >10, 5% [249].                                                                                                                                   
High eosinophil count at baseline have also been associated with more favorable outcome in 
ipilimumab treated patients and increase in absolute eosinophil count towards the end of 
treatment was shown to correlate with better OS [250].                                                                           
MDSCs have also been associated with treatment response to ipilimumab. Low frequency of 
MDSCs at baseline have been associated with the higher probability of long term survival 
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compared to high levels in ipilimumab treated patients [249]. This correlation has also been 
studied by our group, although we found that the frequency of MDSCs after the first cycle of 
ipilimumab correlated with outcome and clinical benefit, not the baseline frequency.                                                              
Neutrophil to Lymphocyte Ratio (NLR) is used as a marker of subclinical inflammation and 
is also associated with worse outcomes in several malignancies. Baseline NLR and changes 
in NLR during treatment is associated with overall survival, progression-free survival, and 
clinical response in patients treated with immunotherapy. A high NLR, no matter measured 
prior to or during treatment with ipilumumab, was associated with worse OS, PFS, and 
clinical response and an increasing NLR from baseline during treatment was correlated with 
worse OS and PFS in ipilimumab-treated patients [251].                                                                                                      
Increases in absolute lymphocyte count and in percentages of CD4+ and CD8+ T cells during 
treatment have been associated with improved survival in ipilimumab treated patients [250]. 
Clinical or host parameters associated with response to ICI 
Some studies have demonstrated that there are gender differences in tumor immunity, which 
are associated with gender different anti-tumor immune responses in general [252]. Even 
though not many have been able to show any correlation between gender and response to ICI, 
meta-analyses have shown relation between gender (in the favor of men) and PFS and OS in 
patients treated with ICI [253]. It has been shown that males were associated with better ORR 
to anti-PD1 treatment [254]. In addition to this, an association between obesity and better 
PFS and OS at treatment with ICI (and targeted therapy), especially in men, has been shown 
[255].                                                                                                                                            
Response to pembrolizumab in melanoma patients over age 60 has been demonstrated to be 
significantly higher than those below 60 years and the likelihood of response increased with 
age [256]. It has also been demonstrated that that ages above 65 correlated with better ORR 
in patients treated with anti-PD-1 [254]. But there are opposing results reported [257] why no 
consensus regarding age and the prediction of response exists.                                                                                                   
Uveal and mucosal melanoma subtypes are known have a lower mutation burden (due to the 
fact they are not exposed to excessive UV radiation that leads to increased DNA damage and 
mutations) than skin melanoma and are consequently associated with low response rates to 
ICI. However some favorable responses have been described for mucosal melanoma to anti-
PD1 [258, 259].                                                                                                                                  
Visceral metastases, especially liver metastases have been associated with less response to 
ICI [260].                                                                                                                                          
Earlier treatment might also influence the response to and outcome of ICI treatment. Several 
studies have demonstrated lower response rates to anti-PD-1 in previously treated patients 
[172]. This fact could be theoretically biologically contradictory as earlier therapies such as 
chemotherapy or radiotherapy could contribute to increased mutational load, increased 
antigen release and thereby ultimately enhanced T cell activity.                                                              
A higher gastrointestinal microbiodiversity has been associated with positive response to ICI 
[261]. It is shown that patients who consume greater dietary fiber and thereby have increased 
diversity of gut flora have better responses to ICI [262]. Patients having consumed 
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antibiotics, regardless of type, prior to ICI therapy have been shown to have worse outcome, 
but antibiotics during ICI treatment have not been shown to worsen outcome [262].                                                                                                                                  
Presence of an irAE indicates that ICI has caused its intended phamacodynamic effect: 
immune activation. In melanoma patients treated with nivolumab those who experienced any 
irAE had a significantly longer OS than those who did not, with an additional benefit in OS 
for those with 3 or more irAEs compared with patients with none or 1 irAE [263]. Especially 
cutaneous irAEs, such as rash and vitiligo, have been associated with improved OS [263].  
 
All in all the effort of trying to find biomarkers seem to be almost untiring and hopefully it 
will eventually result in something substantial to use in the clinical setting, as it is of great 
importance to reduce the use of treatment not offering help, potentially causing side effects 
and potential harm. Utopic the ideal biomarker for response is one that is easy to obtain, easy 
to analyze, easy to interpret, does not cost much and is convenient to use in the clinical 
setting. This means that parameters in blood that could be analyzed and used as potential 
biomarkers are easy and favorable to use in the clinical setting, as that does not mean much 
harm to patients, it could be used in clinical routine when the patients leave blood for 





1.3.7 Additional promising but not approved treatments  
Even though there is so much more to offer patients with advanced melanoma and by that 
also much more hope to be able to give, there is still limited hope to offer to the group of 
patients that do not respond already upfront or progress after initial response.         
One method of treatment suitable for a limited number of these patients is adoptive cell 
therapy with TILs with or without DC vaccination. Adoptive cell therapy with autologous 
TILs can have the ability to mediate tumor regressions despite progression on ICI [264-266].              
Adoptive cell therapy with TIL to lymphodepleted patients, together with IL-2, to support the 
persistence of the TILs, has resulted in a high rate of clinical responses, with response-rates 
>50% and along with that also durable responses [117]. Until recently this method was, when 
selecting the right type of patients, the most effective therapy of metastasized melanoma, 
before the combination of anti-CTLA-4 and anti-PD-1 took over this position.                     
Adoptive cell therapy with TIL was developed more than 30 years ago by Steven Rosenberg 
and colleagues at the Surgery Branch of the NCI.                                                                        
Despite the high and durable responses, this treatment method has not made its way to 
become an approved method in clinical routine. The reason for this could be several-fold. The 
production of TILs is a demanding, complex process and the treatment, especially with its IL-
2 support is associated with, sometimes, severe toxicity (high fever, chills, hypotension, 
capillary leak syndrome, electrolyte derangements). As the treatment is not approved, it is 
mostly used as last-line treatment. Patients with advanced melanoma progressing on 
approved therapy are a vulnerable group of patients as the disease in many cases could 
progress very rapidly and their ability to tolerate toxicity could be limited. Therefore, with the 
long and complex production of TILs and the sometimes harsh toxicity, far from all patients 
progressing on ICI are suitable for this treatment.  But when selecting the appropriate patients 
it is, despite its toxicity profile, a very good treatment that could offer prolonged overall 
survival and symptom-relief beyond check-point blockade.     
  
Figure 12. ACT with DC vaccination                      
              (L. Rehn, 2017) 
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1.4 FINAL REFLECTIONS FROM A CLINICIAN  
With all new knowledge and new treatments in mind, could my relative have had a longer 
period of symptom relief or even becoming free of disease, had the disease recurred later or 
today. It seems to me that the course of recurrence was very rapid and that his performance 
status along with that also deteriorated very rapidly. One could imagine that the LDH level 
was elevated by the time of stage IV diagnosis, so from a clinical perspective it seems like 
there would not have been any indication for single ICI with anti-PD1, and combination ICI 
would have caused a much too high risk of toxicity that he would not have been able to 
tolerate. If the tumor would had had a BRAF mutation, it would have been indicated to treat 
him with BRAF/MEK inhibitors, since I believe that he could have handled the toxicity and 
that could have given him some more time and some symptom relief. But thinking that he 
would have become a long lasting responder with that rapid disease progression is unlikely. 
Then at progression, if treated with and responding to targeted therapy, it is likely that the 
disease would have taken the stormy rapid course again, which often is the case, not allowing 
for second line with immune therapy. That fact also would not have made him suitable for 
ACT with TIL with or without dendritic cell vaccination since the production time would 
have had exceeded his survival. If there was no BRAF mutation, then he would have been left 
with exactly what he was left with, best supportive care or maybe temozolomide, which 
perhaps he would have tolerated, but not likely bringing him benefit. That we have to bear in 
mind, that even though there has been a revolution going on right in front of our clinical eyes, 
best supportive care, is still sometimes what we are left with. That might not even be the 
worst alternative considering the sometimes harsh toxicity and the risk of spending 
considerable valuable time in hospital. Still we are very focused on winning time and offering 
some type of treatment and I believe that it is of importance that we communicate with the 
patients so that they are properly informed what and if they might be gaining from the 
treatment, because perhaps all they have heard is that the “Nobel prize treatment” is like a 
magical solution. Perhaps the patients actually do not value time and any type of treatment 
more than being autonomous, but are driven by relatives or societal factors focusing on time 
and longevity. It is easy for us only to focus on new strategies, but with these new treatments 
our responsibility gets wider, we also have to inform the patients and their relatives when and 
if there is something to favor from the treatment. I believe that is important to bear in mind 
that despite the revolution sometimes we are left with what we had before the revolution and 
respect that as a part of our profession as well. 




2 AIMS OF THE THESIS 
 
 
The overall aim of the thesis is to identify mechanisms of action in the immune system that 
could correlate with clinical response and toxicity to treatment with ICI using anti-CTLA-4 
and anti PD-1 antibodies. In addition, another aim was to conduct a phase I trial with 
adoptive T cell therapy with or without dendritic cell vaccination aiming for approval to offer 
this type of treatment to more patients. 
 
Specific aims 
2.1 PAPER I  
• To study the immune system of patients with MM treated with anti-CTLA4, 
ipilimumab 
• To investigate potential mechanisms of action that could correlate with treatment 
outcome and toxicity 
2.2 PAPER II  
• To study the immune system of patients with MM treated with anti-PD1, nivolumab 
or pembrolizumab  
• To investigate potential mechanisms of action that could correlate with treatment 
outcome and toxicity. 
2.3 PAPER III  
• To perform a phase I trial to evaluate the safety, feasibility and immunologic response 
of adoptive T cell transfer with or without dendritic cell vaccination in patients with 
MM progressing on approved standard treatments. 




3 PATIENTS AND METHODS 
 
3.1 PATIENTS 
3.1.1 Paper I 
Forty-three patients with metastasized stage IV melanoma according to AJCC gave written 
informed consent to participate in the trial while treated with ipilimumab at Radiumhemmet, 
Karolinska University Hospital during the period of July 2012 until May 2015. The first 6 
patients were included in a multicenter clinical trial, CA184-169 receiving ipilimumab at 3 or 
10 mg/kg every three weeks for up to four cycles and the others were treated according to 
clinical routine, receiving ipilimumab at 3 mg/kg every three weeks for up to four cycles.  
Peripheral blood samples for analytical purpose were collected at three time points; before the 
first cycle, before the second cycle and before the fourth cycle. 
3.1.2 Paper II 
Between February 2015 and July 2018 36 patients with metastasized stage IV melanoma 
according to AJCC gave written informed consent to participate in the trial while treated with 
anti-PD-1, either nivolumab every other week or every four weeks, or pembrolizumab every 
three weeks at the Department of Oncology Karolinska University Hospital. 
Peripheral blood samples for analytical purpose were obtained at three time points; before the 
start of the first cycle, before the second cycle and before the fourth cycle. 
3.1.3 Paper III  
The phase I, MAT-02 trial was conducted between October 2013 and May 2018. Patients 
eligible for the trial were 18-74 years old, had progressive and inoperable stage III or stage IV 
(according to AJCC) malignant melanoma with measurable disease (according to Recist 1.1), 
were ambulatory in performance status 0-2 (according to ECOG) with a life expectancy of at 
least 3 months and had a tumor lesion available for surgery or for core biopsy. Main 
exclusion criteria were active CNS metastases, severe comorbidity or active autoimmune 
disease.  
Blood samples for analytical purpose with immune monitoring were collected at several time 








3.2.1 Paper I  
According to clinical routine, blood samples including complete blood count, electrolytes, 
creatinine, liver status and thyroid status, as well as the performance status of the patient and 
evaluation of any AEs were assessed before each cycle of ipilimumab was administered. The 
patients underwent radiological evaluation with computed tomography approximately one 
month after the last cycle of treatment. The response of the patients included in the trial 
CA184-169 was assessed according to WHO criteria and for the other patients in general 
according to immune related response criteria, irRC, but not in a formalized manner. AEs 
were graded 0-5, according to National Cancer Institute Common Terminology Criteria for 
AEs version 4.0 (CTCAE 4.0). 
Collected blood was analyzed for counts of leukocytes, neutrophils, lymphocytes and 
eosinophils as well as for peripheral blood mononuclear cells. PBMCs were obtained from 
the blood samples by ficoll density gradient centrifugation within 1 hour of sample collection. 
Purified PBMCs were used immediately for flow cytometry staining and analysis or 
cryopreserved in fetal calf serum with 10 % DMSO. Fresh PBMCs were after proper titration 
stained according to the manufacturer’s recommendations. Dead cells were excluded using a 
specific kit (see the original article). Cells were then analyzed using an LSRII flow cytometer 
and FlowJo software, using a non-stained control for each sample and fluorescence minus 
one control for critical stainings. A specific gating strategy for each of the populations 
analyzed was used. Quality control of the flow cytometer’s performance and CV values were 
performed daily.  
3.2.2 Paper II 
According to local clinical routine, patients provided blood samples including complete blood 
count, electrolytes, creatinine, liver status, thyroid status before every cycle of anti PD-1 
antibody and those, along with the clinical general condition of the patients and any AEs 
were assessed before each new cycle was administered. Patients underwent the first 
radiological evaluation approximately three months after the start of treatment. Thereafter 
approximately every three months depending on the response and the clinical condition of the 
patient. The radiological evaluation was not made strictly according to irRC. The evaluation 
of response was made by weighing together clinical outcome and radiological evaluation.  
From peripheral blood counts of leukocytes, neutrophils, lymphocytes and eosinophils were 
measured. PBMCs were purified from the blood samples by ficoll density gradient 
centrifugation within 1 hour of sample collection. Regarding the staining and flow cytometry, 




3.2.3 Paper III  
The MAT-02 trial was divided in two cohorts: cohort A where the patients were treated with 
T cell transfer alone and cohort B where dendritic cell vaccinations were added. Both cohorts 
were treated with lymphodepleting chemotherapy consisting of cyclophosphamide and 
fludarabine before T cell transfusion and with intravenous IL-2 after T cell transfusion for the 
persistence of the infused T-cells. Before start of the lymphodepleting regimen the patients 
underwent leukaferesis twice, the first time to generate material for the production of the 
vaccine and the second time to create a rescue bank of stems cells in case of extended 
leukopenia. Toxicity was assessed according to CTCAE 4.0, clinical efficacy was assessed 
with [18F]-FDG PET/CT and evaluated according to RECIST 1.1. 
 
 
Autologous young TILs were expanded from one or several excised melanoma tumors, or 
when no excisable tumor available, retrieved from a core biopsy. Briefly, tumor material was 
minced into 1-3 mm3 fragments that were put into cultures where T cell outgrowth was 
stimulated by addition of high dose IL-2. Once enough T cells could be collected (after 2-4 
weeks), a rapid expansion protocol (REP) was performed to massively increase T cell 
numbers. This was done by culturing TILs with an excess of irradiated autologous PBMCs as 
feeder cells for 6-7 days and thereafter in WAVE bioreactors (GE Healthcare) for another 7-8 
days. Harvested TIL were re-suspended in NaCl and immediately transferred to patients as an 
intravenous infusion. 
Figure 13. Overview of the MAT02 clinical trial with the cohorts A and B, timeline and procedures 
related to the treatment.                                                                                
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For the production of DC vaccine, tumor lysate was generated by freeze-thawing of a tumor 
fragment from the same tumor that was used for TIL generation. DCs were generated from 
monocytes enriched from one of the leukapheresis of the patient. Monocytes were cultured 
for a couple of days and the immature DCs were thereafter loaded with tumor lysate and 
matured. A portion of the matured DCs were harvested and incubated with NY-ESO-1 and 
thereafter mixed together with the rest of the matured DCs. All mature DCs were frozen and 
on the day of the vaccination one vial was thawed, washed and re-suspended in NaCl before 
giving as intradermal injection.  
Blood samples were collected before and at several time-points after TIL infusion. PMBSs 
and TILs were analyzed for T cell maturation and exhaustion by flow cytometry. TIL 
samples were also analyzed for T cell-specificity, using MHC-multimers for known shared 
melanoma TAAs.  
Deep-sequencing of the TCRB (T cell receptor beta chain) gene complementarity 
determining region 3 (CDR3) was performed on the final TIL product as well as on PBMC 
samples collected before and after therapy to identify high frequency T cell clones. 







4.1 PAPER I  
Most patients were in good general condition at treatment initiation with ipilimumab. The 
median overall survival was 39 weeks. Just above 60% of the patients could receive all four 
cycles and the most common reason for not receiving all four cycles was AEs. More than half 
of the patient cohort experienced AEs of any grade and almost one third experienced AEs of 
grade 3 or higher. The AEs could in general be managed with withdrawal of treatment or 
corticosteroids or in a few cases with TNF-alfa antagonist, not causing any long-lasting 
sequel for most of the patients. The objective response rate was 19% with no patient 
obtaining complete response. The patients were divided in two groups for analytical purpose, 
those with clinical benefit (response and stable disease) and those with no clinical benefit 
(progressive disease). The patients with clinical benefit had significantly longer median 
overall survival. 
Absolute lymphocyte counts, eosinophils, effector T cells and their activation status were 
increased in the patient cohort. Additionally, suppressor cells such as T regulatory cells and 
polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) were diminished and 
these effects were observable at the end of treatment and after one cycle, respectively. Total 
eosinophil count correlated to onset of AEs. Monocytic MDSCs decreased during treatment 
in patients with clinical benefit and patients with a lower frequency of these cells after the 
first cycle had increased overall survival. CD8+ effector memory T cell frequencies at the end 
of treatment were higher in patients with clinical benefit and correlated with longer survival. 
4.2 PAPER II  
At the time of treatment initiation with anti-PD-1antibodies most patients were in good 
general condition, 39% had elevated LDH and 69% were treatment naïve. At the time of data 
cut-off the majority of patients had died (47%). Median overall survival was 126 weeks and 
median progression free survival was 38 weeks. Objective response was seen in 50% of the 
patients out of which 28% had complete response and 22% had partial response and 36% of 
the patient cohort had progressive disease. 36% of the patients discontinued treatment due to 
complete response or durable stable disease.  Patients were divided into short PFS (<6 
months) and long PFS (>6 months). 20 patients had long PFS and among these 10 with CR, 7 
with PR, 1 MR, 2 SD and the median overall survival for the patients with short PFS being 45 
weeks and for the patients with long PFS 170 weeks. Treatment related adverse event of any 
grade occurred in almost 60% of the patients and grade 3 or higher in almost 15%. The AEs 
were in general easily managed with corticosteroids.  
No significant changes were seen in absolute counts of leukocytes, lymphocytes, eosinophils, 
neutrophils or monocytes. The number of neutrophils and monocytic MDSCs correlated with 
survival. It was observed that patients with short PFS had higher levels of neutrophils and 
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high number of MDSCs at baseline. It was also observed that patients with high number of 
MDSCs at baseline had correspondingly shorter median OS. In addition, it was observed that 
patients with low frequencies of CD69+ NK cells at baseline had both longer PFS and OS. 
PD-L1 expression in different monocytic subsets was significantly increased in patients with 
shorter PFS and correlated inversely with OS. 
 
4.3 PAPER III  
Of 14 patients with progressive metastatic melanoma enrolled in the MAT-02 study 10 were 
treated. All enrolled patients except one had received and progressed on ICI.  
In cohort A, all treated patients showed a mixed response or stable disease. However, these 
responses were not durable, with an overall survival ranging between 4 and 17.5 months. 
In cohort B, five patients were enrolled and commenced therapy as per protocol. One patient 
died before receiving the DC vaccine and was not evaluable for response. Of the four patients 
receiving the complete combined TIL and DC -treatment, all had an objective response 
according to RECIST 1.1. These responses consisted of two durable complete responses, one 
durable high-quality partial response and 1 short-term partial response. The short-term 
response was only considered a mixed response by irRC. 
All 10 patients received the lymphodepleting chemotherapy. 
The majority of patients reacted with mild to moderate toxicity, such as fever and chills 
following the TIL transfusion which often was successfully treated with paracetamol.                    
The most severe AEs in the trial occurred in response to IL-2 therapy. In cohort A, four of 
five treated patients received all 14 doses of IL-2, whereas in cohort B, none of five patients 
received all doses. The main reason for stopping IL-2 infusions was capillary leakage, a 
known side-effect of IL-2 therapy.                                                                                               
One patient died during the course of treatment. After ending the IL-2 treatment the patient 
suddenly desaturated and was treated at the intensive care unit. Despite all at the intensive 
care unit resources the patient died, most likely due to metabolic acidosis, a known but rare 
toxicity of IL-2 treatment.                                                                                                                 
None of the four patients in cohort B receiving the DC-vaccinations experienced any 
particular toxicity to these injections.  
The production of TILs was possible for all patients. The median production time for TILs 
was 35 days. The median yield given back to the patient was 10,3E9 for cohort A and 42E9 
for cohort B. The production was however less successful for 3 patients in cohort A, which in 
all three cases was due to slow expansion in the REP step. The viability of the T cell product 
at final harvest was high (mean 97%), and the cultures from most of the patients were 
predominantly T cells, with a strong skewing towards the CD8+ subpopulation. 
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Patients in cohort B received a tumor lysate-loaded DC-vaccine produced from monocytes 
enriched by elutriation from a leukapheresis product. The enriched product contained 93% 
monocytes. After DC differentiation and tumor lysate-loading, mDC showed a mature 
phenotype with high viability. Four patients in cohort B received five doses of intradermal 
DC vaccine with high viability. The effect was clinically assessed by a DTH test for the 
tumor lysate and the NY-ESO-1 peptide. None of the patients reacted to the tumor lysate, but 
one patient reacted with skin reaction to the NY-ESO-1 peptide.  
An important factor for reaching any efficacy from ACT is the number of infused cells and 
their longevity. To study this, as mentioned above, both immune monitoring and deep 
sequencing of the TCRB gene were performed, with the intention to monitor the infused 
TILs.  
The TCRB sequencing showed that the infused cells survived for a durable period and that 
the survival was the longest among the cells infused to patients experiencing partial response 
with long duration, probably due to continuous proliferation in response to the remaining 
tumor burden. Immune monitoring data revealed that the TILs contained both CM and EM T 
cells, but that they after the infusion continued to differentiate with an increase regarding the 
EMRA population and a decrease regarding the CM population, most probably due to that the 
cells came in contact with tumor cells and later also DC from the vaccination. In accordance 
with this, the expression of the activation and exhaustion marker PD-1 increased in most 
patients in T cells in blood following ACT. Increased expression of PD-1 could be a sign of 
exhaustion of the cells meaning a negative effect on the treatment, but despite many of the 
responding patients had an increase in the PD-1 expression, none of them has yet revealed 




5 CONCLUSIONS, DISCUSSION AND IMPLICATIONS 
 
5.1 PAPER I  
The clinical efficacy of the treatment was in concordance with what has been shown before 
and what is a general clinical opinion when using ipilimumab as single agent. We found that 
immune cells other than T cells are important during check point blockade with anti-CTLA-4 
and that effects on those cells correlated with outcome. Even though ipilimumab does not 
have the same position in the clinical setting as it had in the beginning after the approval, 
currently the use of it together with or sequentially with anti-PD-1 is in practice. Our data 
could potentially help guiding the clinical decisions, by observing the number of MDCS cells 
and the number of CD8+ effector memory T cells at different time points, at baseline, after 
the first treatment and towards the end of ipilimumab treatment in order to guide if another 
drug should be added or if it is time to end treatment. If, for instance the decision to start 
ipiliumumab after progression on anti-PD-1 is taken, the situation could be that of a 
vulnerable patient in progression, not tolerating extensive toxicity and potentially not 
benefitting of another ICI. Then MDSCs after the first treatment could help to guide 
continued treatment, if they do not go down compared to baseline (before ipilimumab) then 
perhaps considering to halt the treatment is in place, as our data implicates that patients with 
low MoMDCSs already after the first cycle are the ones benefitting from ipilumab. If anti-
PD-1 is considered after progression on anti-CTLA-4, the number of CD8+ effector memory 
T cells could be monitored to, in addition to the performance status of the patient, be of 
guidance in how to proceed with therapy. If the numbers of CD8+ effector memory T cells 
are low and the patient is in weak general condition, then perhaps it is time to start to consider 
switching to targeted therapy (if there is a BRAF mutation) instead, as our data implicated that 
patients with low CD 8+ effector memory T cells towards the end of ipilimumab treatment in 
addition to not benefitting from the treatment also had worse overall survival. If the numbers 
of CD8+ effector memory cells on the other hand  are high but the patient is still in stable 
clinical condition, then one perhaps could have the courage to “wait and see”, before starting 
another line of therapy.  
5.2 PAPER II  
Also in this investigation we could observe that the clinical efficacy of the treatment with 
anti-PD-1 was in coherence with what has already been reported. Although more patients 
have benefit from the treatment with anti-PD-1 and although the number of patients 
experiencing limiting toxicity is lower than with the treatment with anti-CTLA-4, there is still 
a considerate number of patients, not experiencing efficacy. It is of great importance to find 
biomarkers that reliably and at low cost could allow for pretreatment selection, so that 
treatment could be offered only patients who will benefit. It is also of great importance to find 
biomarkers that are easy to use in the clinical setting. Routine hematological evaluation is one 
of the ideal sources of predictive and prognostic biomarker due to the fact that it incorporated 
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in the clinical routine, does not put the patients at any direct risk and is of low cost. In this 
work we could show that certain cells extracted from routine blood work and further prepared 
and analyzed could be interesting as potential biomarkers, although further exploration and 
correlation to the clinical outcome is needed. We also found in this work that other cells than 
T cells, such as subtypes of NK cells and subtypes of MDSC’s  are involved in the blockade 
of anti-PD-1 and that they after further exploration, perhaps could be used as potential 
biomarkers. These results, if they could be further explored and taken into practice means that 
the cooperation between the laboratory world, the bench, and the clinical world is of certain 
importance and that translational work and cooperation, even in in the caretaking of the 
patients is of great importance.  
5.3 PAPER III  
The MAT02 trial could be conducted in a safe way with limited and expected toxicity and it 
was shown that this type of treatment can be offered to selected patients with advanced 
melanoma having progressed on approved therapy including check-point inhibitors, 
regardless of earlier response to check-point inhibitor therapy. The selection of patients has to 
be thorough, as one patient unfortunately succumbed after IL-2 treatment. This sheds light on 
the importance of the selection of patients and on the time point when this treatment should 
be offered. At present the TILs are generated from material obtained when the patient has 
progressed on approved therapy. This could, in order to improve the trial and perhaps the 
outcome, be performed earlier. The optimal scenario would be to take tumor samples from 
patients with available lesions before starting check-point therapy and to save the material for 
possible later use for ACT therapy. This would make the production time shorter when the 
patients have progressed and would minimize the risk of the patients progressing during the 
production time. Perhaps this therapy could be offered earlier to a selected number of 
patients, possibly before starting check-point therapy. That would mean that the selected 
patients are in better performance status and hopefully enable clinicians to handle the toxicity 
more efficiently. If there is a good response which is followed by progression at a later time, 
the treatment could perhaps be offered again. If the situation is opposite, the patient could 
then be treated with other approved immune therapy or even targeted therapy and perhaps 




6 FUTURE PERSPECTIVES 
 
When having taken part of a revolution and having the situation before and after that 
revolution in memory it is easy to become blinded by the progress the revolution has led to. 
Remembering the patients with galloping melanoma and remembering the feeling of 
powerlessness not being able to offer them anything could perhaps to some extent make us 
blinded by the success of the new groundbreaking therapies, by the fact that we actually have 
something to offer, no matter the result and the dark side. However, it is important to bear in 
mind that a revolution does not take place at all levels and that there are costs behind it.  
The therapies will continue developing and we have to be careful that we do not get lost in 
the jungle of development and forget the patients behind the disease. We have to be cautious 
in order not to be blinded by the new strategies that will develop just because we remember 
how it used to be when there was nothing to offer. It is important to really consider what and 
how much the therapies really offer the patients so that we do not end up offering them 
treatment just because we are able to. It is important that we continue to keep our heads clear 
and cold so that we do not get carried away, forgetting the humans behind the overall survival 
numbers and not forgetting to consider if the numbers really are that good. We could be 
balancing on a very thin line and it is easy to fall if we get carried away not considering when 
to stop treating. Therefore, it is of importance to repeatedly discuss these matters, to 
repeatedly reconsider our decisions and to examine our decisions and why we decide in a 
certain way.  
It is also important to consider the societal costs for these new strategies, and the resources 
they take up, both economically and ecologically. I believe that the burden these new 
therapies take up, both economically and resource-wise are something that we will be 
discussing in the future more and more. For how long will we be able to offer these 
treatments to this limited group of people? Must we not start thinking about reducing the 
incidence? Can we defend these treatments if we do not try to minimize the people getting the 
primary disease? (Maybe it is time to take action with the summer tours, caravaning the 
beaches again?) I believe that we have to start taking our responsibility as oncologists to a 
wider perspective, not just offering the patients more and more treatments or trying to fit 
them into more trials offering more and more combinations. Instead we have to broaden our 
way of working and consider primary prevention, toxicity, time spent in hospital, quality of 
life during treatment to greater extent and put the rates and data from the trials in a wider 
consideration, are they really that good considering the toxicity, the hospitalizations and the 
costs?  
Of course, the new revolutionizing treatments already approved are a true revolution but 
considering what has been reflected upon above we continuously have to question and 
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